WO2003027251A2 - Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation - Google Patents

Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation Download PDF

Info

Publication number
WO2003027251A2
WO2003027251A2 PCT/US2002/030499 US0230499W WO03027251A2 WO 2003027251 A2 WO2003027251 A2 WO 2003027251A2 US 0230499 W US0230499 W US 0230499W WO 03027251 A2 WO03027251 A2 WO 03027251A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyrin
nbs
ofthe
test compound
polypeptide
Prior art date
Application number
PCT/US2002/030499
Other languages
English (en)
Other versions
WO2003027251A3 (fr
Inventor
John Bertin
Gulam. A. Manji
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/027,629 external-priority patent/US20020197660A1/en
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Priority to AU2002362604A priority Critical patent/AU2002362604A1/en
Publication of WO2003027251A2 publication Critical patent/WO2003027251A2/fr
Publication of WO2003027251A3 publication Critical patent/WO2003027251A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the CED4/Apafl family of proteins are intracellular, receptor-like molecules that coordinate the assembly of signaling complexes that regulate the activation of NF-kB, cytokine processing, and apoptosis.
  • Human members of this family include: Apafl, CARD4
  • Each family member contains a CARD domain that mediates assembly with a downstream CARD- containing signaling partner, and a nucleotide-binding site that regulates activation ofthe signaling complex.
  • each member contains a domain of either WD-40 repeats
  • LRR leucine-rich repeats
  • CARD4, CARD7, Nod2 and CARD 12 leucine-rich repeats
  • the NBS/LRR structure of CARD4, CARD7, Nod2 and CARD 12 is strikingly similar to the plant NBS/LRR family of signaling proteins that induce gene expression and cell death in response to pathogen infection.
  • plant NBS/LRR proteins contain either a leucine zipper motif or a Toll/iriterleukin-1 receptor homology region in place of a CARD domain.
  • NF-kB nuclear factor- ⁇ B
  • NF- ⁇ B NF- ⁇ B binding to I B causes to remain in the cytoplasm.
  • stimuli that activate NF- ⁇ B are known (New England Journal of Medicine 336:1066, 1997) and they include cytokines, protein kinase C activators, oxidants, viruses, and immune system stimuli.
  • NF- ⁇ B activating stimuli activate specific I ⁇ B kinases that phosphorylate I B leading to its degradation.
  • NF- ⁇ B translocates to the nucleus and activates genes with KB sites in their promoters.
  • the proinflammatory cytokines TNF- ⁇ and IL-1 induce NF- ⁇ B activation by binding their cell-surface receptors and activating the NF- ⁇ B-inducing kinase, NIK, and NF- ⁇ B.
  • NIK NF- ⁇ B-inducing kinase
  • NIK phosphorylates the I ⁇ B kinases ⁇ and ⁇ which phosphorylate I ⁇ B, leading to its degradation.
  • NF-KB and the NF- ⁇ B pathway has been implicated in mediating chronic inflammation in inflammatory diseases such as asthma, ulcerative colitis, rheumatoid arthritis (Epstein, New England Journal of Medicine 336:1066, 1997) and inhibiting NF- ⁇ B or NF- KB pathways may be an effective way of treating these diseases.
  • CARD7 and NBS1 are NBS/LRR proteins with N-terminal PYRIN-domains (Bertin and DiStefano, supra).
  • the PYRIN domain is a protein-protein interaction module belonging to the death domain-fold superfamily which includes the CARD, death, and death effector domains (Bertin et al. (2000) J. Biol Chem. 275:41082; Pawlowski et al. (2001) Trends Biochem Sci. 26:85; Martinon et al. (2001) supra; Fairbrother et al. (2001) Prot. Sci. 10:1911.
  • Proteins containing the PYRIN domain share homology with the N-terminal region of pyrin, a protein that functions to regulate inflammatory signaling in myeloid cells (Centola et al. (2000) Blood 95:3223). Mutations within the pyrin gene confer susceptibility to familial Mediterranean fever, a type of hereditary periodic inflammatory disease (The International FMF Consortium, 1997).
  • the apoptosis proteins ASC and zebraf ⁇ sh caspase-13 each contain N-terminal PYRIN domains suggesting that PYRIN family members function in both inflammatory and apoptotic signaling (Masamuto et al. (1999) J. Biol. Chem. 274:33835; Inohara and Nunez, (2000) J. Biol. Chem. 276:2551.
  • NBS-1 and human PYRIN-1 Both NBS-1 and PYRIN-1 have a pyrin domain, so-named for its homology to a portion of pyrin (marenostrin). NBS-1 and PYRIN-1 also have a nucleotide binding site (NBS) domain and a leucine rich repeat domain (LRR) domain, both of which are present in a number of proteins that transmit signals which activate apoptotic and inflammatory pathways in response to stress and other stimuli.
  • NBS nucleotide binding site
  • LRR leucine rich repeat domain
  • the invention features a method for identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5, the method comprising the steps of: a) contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5, or a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 with a test compound; and b) determining whether the polypeptide binds to the test compound.
  • the binding ofthe test compound to the polypeptide is detected by a method selected from the group consisting of: a) detection of binding by direct detecting of test compound/polypeptide binding; b) detection of binding using a competition binding assay; c) detection of binding using an assay for NBS-1 or PYRIN-1 -mediated signal transduction; d) detection of binding using an assay for proteolytic activity; e) detection of binding to a pyrin domain; and f) detection of binding to ASC.
  • the invention also features a method for modulating the activity of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 comprising contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 or a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity ofthe polypeptide.
  • the invention includes a method for identifying a compound which modulates the activity of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5, the method comprising: a) contacting the polypeptide with a test compound; and b) determining the effect ofthe test compound on the activity ofthe polypeptide to thereby identify a compound which modulates the activity ofthe polypeptide.
  • the invention also features a method for identifying a candidate compound for modulating the binding of PYRIN-1 to ASC, the method comprising: a) measuring the binding of a first polypeptide comprising the pyrin domain of ASC to a second polypeptide comprising the pyrin domain of PYRIN-1 in the presence of a test compound; and b) comparing the binding of the first polypeptide to the second polypeptide measured in step (a) to the binding ofthe first polypeptide to the second polypeptide in the absence ofthe test compound, wherein altered binding ofthe first polypeptide to the second polypeptide in the presence ofthe test compound compared the binding in the absence ofthe test compound indicates that the test compound modulates the binding of PYRIN-1 to ASC.
  • the method includes a method for identifying a candidate compound for modulating the ASC-mediated activation of NF-kB, the method comprising: a) measuring the binding of a first polypeptide comprising the pyrin domain of ASC to a second polypeptide comprising the pyrin domain of PYRIN-1 in the presence of a test compound; and b) comparing the binding ofthe first polypeptide to the second polypeptide measured in step (a) to the binding of the first polypeptide to the second polypeptide in the absence ofthe test compound, wherein altered binding ofthe first polypeptide to the second polypeptide in the presence ofthe test compound compared the binding in the absence ofthe test compound indicates that the test compound is candidate compound for modulating the ASC-mediated activation of NF-kB.
  • the invention features a method for identifying an modulator of NF-kB activity, the method comprising: a) providing a cell expressing recombinant ASC and recombinant PYRIN-1 ; b) exposing the cell to a test compound; and c) measuring the NF-kB activity ofthe cell in the presence ofthe test compound, wherein altered activation in the presence ofthe test compound compared to the absence ofthe test compound indicates that the compound is a modulator of NF-kB activity.
  • the invention features a method for identifying a candidate compound for modulating the ASC-mediated activation of NF-kB, the method comprising: a) measuring the binding of a test compound to the LRR domain of PYRIN-1 ; and b) determining that the test compound is a candidate compound for modulating the ASC- mediated activation of NF-kB when the test compound binds to the LRR domain of PYRIN-1.
  • the invention features a method for identifying a candidate compound for modulating the ASC-mediated activation of NF-kB, the method comprising: a) measuring the binding of a test compound to the LRR domain of PYRIN-1 ; and b) identifying the test compound as an LRR domain binding compound when the test compound binds to the LRR domain of PYRIN-1 ; c) measuring the activation of NF-kB in a cell expressing ASC and PYRIN-1 in the presence and absence ofthe LRR domain binding compound, wherein the LRR domain binding compound is a candidate compound for modulating the ASC-mediated activation of NF-kB ifthe activation of NF-kB in the presence ofthe LRR domain binding compound is greater than in the absence ofthe LRR domain binding compound.
  • the invention features a method for identifying a candidate modulator of PYRIN-1, the method comprising: a) contacting a purified polypeptide comprising the NBS domain of PYRIN-1 with a test compound in the presence of a nucleotide that binds to the NBS domain in the absence ofthe test compound; b) measuring the binding ofthe nucleotide to the NBS domain in the presence ofthe test compound; and c) identifying the test compound as a candidate modulator of PYRIN-1 ifthe test compound reduces the binding ofthe nucleotide to the NBS domain.
  • the nucleotide is bound to the NBS domain before the polypeptide is exposed to the test compound, the test compound is exposed to the polypeptide before the polypeptide is exposed to the nucleotide, the nucleotide is selected from the group consisting of an adenine nucleotide, a guanidine nucleotide, a thymidine nucleotide, a cytosine nucleotide, and a uridine nucleotide, the nucleotide is selected from the group consisting of a ribonucleotide and a dideoxribonucleotide, and the nucleotide is selected from the group consisting of: ATP, ADP, TTP, TDP, UTP, UDP, CTP, CDP, GTP, and GTP.
  • the invention features a method for identifying a candidate modulator of PYRIN-1, the method comprising: a)contacting a purified polypeptide comprising the NBS domain of PYRIN- 1 with a test compound in the presence of a nucleotide that binds to the NBS domain in the absence ofthe test compound; b) measuring the binding ofthe nucleotide to the NBS domain in the presence ofthe test compound; c) identifying a test compound that reduces the binding ofthe nucleotide to the NBS domain; and d) measuring the binding of a test compound that reduces the binding ofthe nucleotide to the NBS domain of PYRIN-1 to an NBS domain of a protein other than PYRIN-1; wherein the test compound is a candidate modulator of PYRIN-1 if it reduces the binding ofthe nucleotide to the NBS domain of PYRIN-1 and does not substantially reduce the binding of the nucleotide ofthe NBS domain of a
  • the invention features a method for identifying a candidate modulator of PYRIN-1, the method comprising: a) contacting a purified polypeptide comprising the NBS domain of PYRIN-1 with a test compound in the presence of a nucleotide triphosphate that binds to the NBS domain in the absence ofthe test compound; b) measuring the hydrolysis ofthe nucleotide triphosphate in the presence ofthe test compound; and c) identifying the test compound is a candidate modulator of PYRIN-1 ifthe test compound reduces the hydrolysis ofthe nucleotide triphosphate.
  • the invention features a method for identifying a modulator of caspase-1 activity, the method including: a) providing a cell expressing recombinant PYRIN-1; b) exposing the cell to a test compound; and c) measuring caspase-1 activity of the cell in the presence ofthe test compound, wherein altered caspase-1 activity in the presence ofthe test compound compared to the absence ofthe test compound indicates that the compound is a modulator of caspase-1 activity.
  • a fragment of PYRIN-1 e.g., a fragment containing the pyrin domain
  • a cell can also express recombinant ASC, caspase-1, and/or a fragment of ASC or caspase-1.
  • Caspase-1 activity can be detected, for example, by measuring the presence of protein products produced by caspase-1 proteolytic activity (e.g., detecting IL-1 ⁇ secretion).
  • the method can also include an additional step of measuring the caspase-1 activity of the cell in the absence of the test compound and/or in the absence of PYRJN-1 (e.g., recombinant PYRIN-1).
  • the invention features a method for identifying a candidate modulator of PYRIN-1, the method including: a) contacting a purified polypeptide containing the pyrin domain of PYRIN-1 with a test compound in the presence of caspase-1 and a caspase-1 substrate; b) measuring the proteolysis ofthe caspase-1 substrate in the presence ofthe test compound; and c) identifying the test compound as a candidate modulator of PYRJN-1 ifthe test compound modulates the proteolysis ofthe caspase-1 substrate.
  • the caspase-1 substrate can be a unprocessed form of a cytokine, e.g., pro-IL-1 ⁇ , wherein caspase-1 proteolysis results in the formation of a bioactive form of the cytokine, e.g., bioactive IL-l ⁇ .
  • the method can also include an additional step of measuring the proteolysis ofthe caspase-1 substrate in the absence ofthe test compound and/or comparing the proteolysis of the caspase-1 substrate in the absence ofthe test compound with that measured in the presence ofthe test compound.
  • the invention also features a method for modulating ASC activity in a patient, the method comprising administering a compound that alters the activity of PYRIN-1, a method for modulating NF-kB activity in a patient, the method comprising administering a compound that alters the activity of PYRJN-1, and a method for treating an inflammatory disorder in a patient, the method comprising administering a compound that alters the activity of PYRIN-1.
  • the above described methods can also be used for identifying a candidate compound for treating an inflammatory disorder.
  • the present invention provides a method for detecting the presence of NBS-1 or PYRIN-1 activity or expression in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of NBS-1 or PYRJN-1 activity such that the presence of NBS-1 or PYRIN-1 activity is detected in the biological sample.
  • the invention provides a method for modulating NBS-1 or PYRIN - 1 activity comprising contacting a cell with an agent that modulates (inhibits or stimulates) NBS-1 or PYRIN-1 activity or expression such that NBS-1 or PYRIN-1 activity or expression in the cell is modulated.
  • the agent is an antibody that specifically binds to NBS-1 or PYRIN-1 protein.
  • the agent modulates expression of NBS-1 or PYRIN-1 by modulating transcription of a NBS-1 or PYRIN-1 gene, splicing of a NBS-1 or PYRJN-1 mRNA, or translation of a NBS-1 or PYRIN-1 mRNA.
  • the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand ofthe NBS-1 or PYRIN-1 mRNA or the NBS- 1 or PYRIN- 1 gene.
  • the methods ofthe present invention are used to treat a subject having a disorder characterized by aberrant NBS-1 or PYRJN-1 protein or nucleic acid expression or activity or related to NBS-1 or PYRLN-1 expression or activity by administering an agent which is a NBS-1 or PYRLN-1 modulator to the subject.
  • the NBS-1 or PYRIN-1 modulator is a NBS-1 or PYRIN-1 protein.
  • the NBS-1 or PYRIN-1 modulator is a NBS-1 or PYRIN-1 nucleic acid molecule.
  • the NBS-1 or PYRIN-1 modulator is a peptide, peptidomimetic, or other small molecule.
  • the present invention also provides a diagnostic assay for identifying the presence or absence ofa genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a NBS-1 or PYRJN-1 protein; (ii) mis-regulation of a gene encoding a NBS-1 or PYRIN-1 protein; (iii) aberrant RNA splicing; and (iv) aberrant post-translational modification of a NBS-1 or PYRIN-1 protein, wherein a wild-type form of the gene encodes a protein with a NBS-1 or PYRJN-1 activity.
  • the invention provides a method for identifying a compound that binds to or modulates the activity of a NBS-1 or PYRIN-1 protein.
  • such methods entail measuring a biological activity of a NBS-1 or PYRJN-1 protein in the presence and absence of a test compound and identifying those compounds that alter the activity ofthe NBS-1 or PYRJN-1 protein.
  • the invention also features methods for identifying a compound that modulates the expression of NBS-1 or PYRIN-1 by measuring the expression of NBS-1 or PYRJN-1 in the presence and absence of a compound.
  • NBS-1 PYRIN-1 and/or ASC may be useful for modulating an inflammatory response, modulating NF-kB activation, modulating apoptotic response, treating inflammatory disorders, e.g., auto- inflammatory disorders and disorders associated with an inappropriate level of apoptosis
  • assays which identify compounds that modulate the activity or expression of NBS-1 or PYRIN-1 can be used to identify candidate compounds for the treatment of such disorders.
  • an assay which identifies compounds that modulate the activity or expression of PYRIN-1 are useful for identifying candidate compounds for the treatment of Muckle-Wells syndrome or familial cold urticaria or arthritis.
  • Such assays can also be used to identify candidate compounds for treatment of other inflammatory diseases such as inflammatory bowel disorders, Crohn's disease, ulcerative colitis, reactive arthritis, rheumatoid arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, respiratory inflammatory diseases and disorders, such as asthma and chronic obstructive pulmonary disease, gastrointestinal allergies, including food allergies, eosinophilia, conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as helminthic (e.g., leishmaniasis), certain viral infections, including HIN, and bacterial infections, including tuberculosis and lepromatous lepros
  • the invention also features methods for treating disorders associated with inappropriate apoptosis (e.g., Alzheimer's diseases or other neurological disorders associated with neuronal apoptosis) by modulating the expression or activity of ⁇ BS-1 or PYRJN-1.
  • disorders associated with inappropriate apoptosis e.g., Alzheimer's diseases or other neurological disorders associated with neuronal apoptosis
  • NBS-1 and PYRIN-1 useful in the method ofthe invention include those containing some or all ofthe full-length polypeptide sequences disclosed herein. In many cases a polypeptide comprising only one or a few domains of NBS-1 or PYRIN-1 will be useful. For example, polypeptides comprising the pyrin domain of PYRIN- 1, but not the LRR domain of PYRIN-1 are useful in certain screening assays.
  • an isolated NBS-1 protein having an amino acid sequence that is at least about 65%>, preferably 75%, 85%, 95%, or 98%> identical to the amino acid sequence of SEQ ID NO: 1
  • an isolated PYRIN-1 protein having an amino acid sequence that is at least about 65%, preferably 75%, 85%, 95%, or 98%> identical to the amino acid sequence of SEQ ID NO:
  • PYRIN-1 protein having an amino acid sequence that is at least about 65%), preferably 75%, 85%, 95%, or 98% identical to the pyrin domain of SEQ ID NO:5 (e.g., about amino acid residues 1-87 of SEQ ID NO:5); an isolated PYRJN-1 protein having an amino acid sequence that is at least about 65%, preferably 75%, 85%, 95%, or 98% identical to the NBS domain of SEQ ID NO:5 (e.g., about amino acids 263-357 of SEQ ID NO:5); an isolated PYRIN-1 protein having an amino acid sequence that is at least about 65%, preferably 75%>, 85%, 95%, or 98% identical to the kinase la domain of SEQ ID NO:5 (e.g., about amino acids 224-233 of SEQ ID NO:5); an isolated PYRIN-1 protein having an amino acid sequence that is at least about 65%, preferably 75%, 85%, 95%, or 98% identical to the kinas
  • ID NO:5 (e.g., about amino acids residues 740-767, 769-796, 797-821, 826-849, 854-878, 883-906, 91 1-935, 940-967, and 968-991 of SEQ ID NO:5) can be useful in the methods of the invention.
  • NBS-1 or PYRIN-1 proteins and polypeptides useful in the methods ofthe invention preferably have at least one biological activity possessed by naturally occurring human NBS- 1 or PYRIN-1, e.g., (i) the ability to interact with proteins in an apoptotic or inflammatory signaling pathway, e.g., ASC and/or caspase-1 ; (ii) the ability to interact with a NBS-1 or PYRIN-1; (iii) the ability to bind to and/or hydrolyze a nucleotide, e.g., ATP or GTP; (iv) the ability to interact with an intracellular target protein; (v) the ability to interact, directly or indirectly, with one or more proteins having a pyrin domain, a CARD domain, or other domain associated with apoptotic and/or inflammatory signaling; (vi) the ability to modulate, directly or indirectly, the activity of a caspase, e.g., caspase-9, caspase-4, cas
  • polypeptides comprising all or a polypeptide fragment of human PYRIN-1 (SEQ ID NO:5) are useful.
  • the polypeptide can posses one or more biological activities of PYRIN-1, e.g., the ability to enhance ASC activation of NF-kB, the ability to selectively interact with ASC (particularly the PYRIN domain of ASC), the ability to co-localize with ASC in cytoplasmic punctate structures, the ability to activate apoptosis, the ability to activate caspase-mediated apoptosis, and the ability to activate caspase-1.
  • the invention also includes polypeptides consisting of or consisting essentially of such polypeptides as well as isolated nucleic acid molecules encoding such polypeptides.
  • polypeptides comprising all or a polypeptide fragment of human NBS-1 (SEQ ID NO:2) are useful.
  • the polypeptide can posses one or more biological activities of NBS-1.
  • the invention also includes polypeptides consisting of or consisting essentially of such polypeptides as well as isolated nucleic acid molecules encoding such polypeptides.
  • NBS-1 or PYRIN-1 proteins ofthe present invention can be operatively linked to a non-NBS-1 or PYRIN-1 polypeptide (e.g., heterologous amino acid sequences) to form NBS-1 or PYRJN-1 fusion proteins, respectively, for use in various screening assays and other methods ofthe invention.
  • a non-NBS-1 or PYRIN-1 polypeptide e.g., heterologous amino acid sequences
  • nucleic acid molecules useful in the methods ofthe invention are those that specifically detect NBS-1 or PYRJN-1 nucleic acid molecules, relative to nucleic acid molecules encoding other members ofthe NBS/LRR superfamily.
  • a NBS-1 or PYRIN-1 nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: l,
  • Such molecules can be, e.g., at least 300 (350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1 100, 1200, 1300, 1400, 1500, 1600, 1800, 2000, 2250, 2500, 2750, 3000, 3250, 3500, 3750, or 3850) nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the cDNA of ATCC , the cDNA of ATCC , or a complement thereof.
  • nucleic acid molecules which includes a fragment of at least 150 (300, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1 100, 1200, 1300, 1400, 1500, 1600, 1800, 2000, 2250, 2500, 2750, 3000, 3250, 3500, 3750, or 3850) nucleotides ofthe nucleotide sequence shown in SEQ ID NO:l , SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the nucleotide sequence of the cDNA of ATCC , the nucleotide sequence ofthe cDNA of ATCC , or a complement thereof.
  • Figures 1 A- IE depict the cDNA sequence (SEQ ID NO:l) and the predicted amino acid sequence (SEQ ID NO:2) of human NBS-1.
  • SEQ ID NO:l extends from nucleotide 78 to nucleotide 3176 of SEQ ID NO:l (SEQ ID NO:3).
  • Figure 2 depicts a hydropathy plot of human NBS-1. Relatively hydrophobic residues are above the dashed horizontal line, and relatively hydrophilic residues are below the dashed horizontal line. The cysteine residues (cys) and potential N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace.
  • Figure 3 depicts a plot showing the predicted structural features of a portion of human NBS-1. This figure shows the predicted alpha regions (Garnier-Robson and Chou-Fasman), the predicted beta regions (Garnier-Robson and Chou-Fasman), the predicted turn regions
  • FIG. 4A-4E depict the cDNA sequence (SEQ ID NO:4) and the predicted amino acid sequence (SEQ ID NO: 5) of human PYRIN-1.
  • the open reading frame of human PYRIN-1 extends from nucleotide 141 to nucleotide 3240 of SEQ ID NO:4 (SEQ ID NO:6).
  • Figure 5 depicts a hydropathy plot of a portion of human PYRJN-1. Relatively hydrophobic residues are above the dashed horizontal line, and relatively hydrophilic residues are below the dashed horizontal line. The cysteine residues (cys) and potential N- glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace.
  • Figure 6 depicts a plot showing the predicted structural features ofa portion of human PYRIN-1. This figure shows the predicted alpha regions (Garnier-Robson and
  • Figure 7 depicts an alignment of amino acids 3-79 of human NBS-1 (amino acid residues 3-79 of SEQ ID NO:2) with the pyrin domains of pyrin (SEQ ID NO:7), CARD-5 (SEQ ID NO:8), and CARD-7 (SEQ ID NO:9).
  • a consensus pyrin domain sequence (SEQ ID NO: 10) is shown above the alignment.
  • Figures 8A-8H each depict the alignment of several ofthe leucine rich repeats within the LRR domain of NBS-1 ((amino acids 726-752 of SEQ ID NO:2 ( Figure 8A), amino acids 782-809 of SEQ ID NO:2 ( Figure 8B), amino acids 811-838 of SEQ ID NO:2 ( Figure 8C), amino acids 839-866 of SEQ ID NO:2 ( Figure 8D), amino acids 868-895 of SEQ ID NO:2 ( Figure 8E), amino acids 896-923 of SEQ ID NO:2 ( Figure 8F), amino acids 925-952 of SEQ
  • Figure 8G depicts an alignment of amino acids 1-82 of human PYRIN-1 (amino acid residues 1-82 of SEQ ID NO:5) with the pyrin domains of pyrin (SEQ ID NO:7), CARD-5 (SEQ ID NO:8), and CARD-7 (SEQ ID NO:9).
  • FIG. 9B depicts an alignment of amino acids 1- 90 of human PYRIN-1 (amino acids 1-90 of SEQ ID NO: 5 with the pyrin domains of pyrin (33% identity), CARD-7 (24% identity), ASC (25% identity), NBS-1 (24% identity), and
  • Figures 10A-10I each depict the alignment of several ofthe leucine rich repeats within the LRR domain of PYRIN-1 ((amino acids 740-767 of SEQ ID NO:5 ( Figure 10A), amino acids 769-796 of SEQ ID NO:5 ( Figure 10B), amino acids 797-821 of SEQ ID NO:5 ( Figure 10C), amino acids 826-849 of SEQ ID NO:5 ( Figure 10D), amino acids 854-878 of
  • SEQ ID NO:5 ( Figure 10E), amino acids 883-906 of SEQ ID NO:5 ( Figure 10F), amino acids 911-935 of SEQ ID NO:5 ( Figure 10G), amino acids 940-967 of SEQ ID NO:5 ( Figure 10H), and amino acids 968-991 of SEQ ID NO:5 ( Figure 101)) with a consensus leucine rich repeat (SEQ ID NO: 13) derived from a hidden Markov model.
  • Figure 11 is a graph depicting the results of an apoptosis assay.
  • Figure 12 is a graph depicting the result of a two-hybrid binding assay for identifying CARD domain which bind to the CARD domain of caspase-1.
  • Figure 13 is a series of blots depicting the results of a co-immunoprecipitation assay in which 293T cells were transfected with expression plasmids encoding HA epitope-tagged ASC and T7 epitope-tagged caspase-1.
  • Cell extracts were immunoprecipitated (IP) with anti-HA immunoblotted (WB) with anti-caspase-1.
  • Figure 14 is a graph depicting the results of an NF-kB activity assay showing that ASC induces NF-kB activity.
  • plasmids expressing ASC were transfected into 293T cells and induction of NF-kB activity was assessed by measuring relative luciferase activity.
  • Figure 15 depicts the results of an NF-kB activity assay showing that PYRIN-1 synergizes with ASC to induce NF-kB.
  • 293T cells were transfected with plasmids expressing PYRIN-1-FL, PYRIN- 1 ⁇ PYRIN, PYPAFI ⁇ LRR, or CARD-9 (500 ng) with or without ASC (32 ng).
  • the amount of DNAs in each transfection was kept constant by addition of empty vectors. Relative luciferase activities were then determined as a measure of NF-kB activity (lower panel). Immunoblot analysis was performed to monitor expression of PYRIN-1 or CARD-9 (upper panel) and ASC (middle panel).
  • Figure 16 depicts the results of an NF-kB activity assay showing that PYRIN-1 and ASC activate NF-kB through the IKK complex.
  • 293T cells were transfected with a plasmid expressing ASC (32 ng) and a plasmid expressing PYRIN-1 (500 ng) and either empty vector (500 ng) or a plasmid expressing dominant negative mutants of IKK ⁇ (IKK ⁇ -DN), or IKK2 (IKK2-DN).
  • Immunoblot analysis was performed to monitor expression of PYRJN-1 (upper panel) and ASC (middle panel). Relative luciferase activities were measured as described (lower panel).
  • Figure 17 depicts the results of a PYRIN-1 mRNA assay in various immune cells.
  • Figure 18 depicts the results of a assay measuring expression of PYRJN-1 in a murine ABT model of rheumatoid arthritis.
  • Figure 19 depicts the results of a assay measuring expression of PYRIN-1 in a murine CIA model of rheumatoid arthritis.
  • Figures 20A and 20B are graphs depicting: (A) the activation of caspase-1, as measured by IL-1 ⁇ secretion, by PYRIN-1 and ASC; and (B) the requirement for active caspase-1 for the induction of IL-1 ⁇ secretion by PYRIN-1 and ASC.
  • PYRIN-1 interacts with ASC, activates NF-kB, and when co-expressed with ASC synergistically activates caspase-1.
  • the pyrin domain of PYRIN-1 is shown to play a central role in these functions, and the LRR domain of PYRIN-1 is shown to act as a negative modulator ofthe PYRIN-1 -mediated activation of NF-kB.
  • the studies demonstrate that PYRIN-1 is a apoptotic signaling molecule that acts in apoptosis and inflammation.
  • a nucleotide sequence encoding a human NBS-1 protein is shown in Figures 1 A-1E (SEQ ID NO:l; SEQ ID NO:3 includes the open reading frame only).
  • a predicted amino acid sequence of human NBS-1 protein is also shown in Figures 1A-1E (SEQ ID NO:2).
  • a nucleotide sequence encoding a human PYRIN-1 protein is shown in Figures 4A- 4E (SEQ ID NO:4; SEQ ID NO:6 includes the open reading frame only).
  • a predicted amino acid sequence of human PYRIN-1 protein is also shown in Figures 4A-4E (SEQ ID NO:5).
  • FIGS. 1A-1E depict the sequence of a 3431 nucleotide cDNA (SEQ ID NO:l) which includes a predicted open reading frame (SEQ ID NO:3; nucleotides 78-3176 of SEQ ID NO:l) encoding a 1033 amino acid human NBS-1 protein (SEQ ID NO:2).
  • Human NBS- 1 is predicted to be an intracellular protein having a molecular weight of 113.6 kD, prior to post-translational modification.
  • the predicted amino acid sequence of human NBS-1 was compared to amino acid sequences of known proteins and various motifs were identified.
  • the 1033 amino acid human NBS-1 protein includes five N-glycosylation sites (e.g., about amino acid residues 637-640, 679-682, 782-785, 789-952, and 952-955 of SEQ ID NO:2); 1 1 protein kinase C phosphorylation sites (amino acids 79-81, 105-107, 218-220, 307-309, 379-381, 563-565, 669-671, 806-808, 983-985, 986-988, and 1016-1018 of SEQ ID NO.2); 16 casein kinase II phosphorylation sites (amino acids 13-16, 55-58, 105-108, 218-221, 229-232, 512-515, 570- 573, 584-587, 639-642, 643-646, 650-653, 669-672, 71 1-714, 791-794, 942-945, and 1027- 1030 of SEQ ID NO:2); two tyros
  • Figure 2 depicts a hydropathy plot of human NBS-1. Relatively hydrophobic residues are above the dashed horizontal line, and relatively hydrophilic residues are below the dashed horizontal line. Potential N-glycosylation sites (Ngly) and cysteine residues are indicated by short vertical lines just below the hydropathy trace.
  • FIG. 3 A plot showing the predicted structural features of a portion of human NBS-1 is presented in Figure 3. This figure shows the predicted alpha regions (Garnier-Robson and Chou-Fasman), the predicted beta regions (Garnier-Robson and Chou-Fasman), the predicted turn regions (Garnier-Robson and Chou-Fasman) and the predicted coil regions
  • NBS-1 amino acid sequence showed it to contain a pyrin domain (about amino acids 3-79 of SEQ ID NO:2) a nucleotide binding site (NBS; about amino acid residues 174-605 of SEQ ID NO:2) and 12 leucine rich repeats (about amino acids residues 670-697, 698-725, 726-752, 754-781, 782-809, 811-838, 839-866, 868-895, 896-923, 925-952, 953-979, and 981-1008 of SEQ ID NO:2) which form a LRR domain (about amino acids 670-1008 of SEQ ID NO:2).
  • NBS nucleotide binding site
  • kinase l a domain (P-loop) (about amino acids 180-195 of SEQ ID NO:2)
  • a kinase 2 domain (Walker B box) (about amino acids 249-264 of SEQ ID NO:2)
  • a kinase 3a domain (about amino acids 302-313 of SEQ ID NO:2).
  • Figure 7 depicts an alignment of amino acids 3-79 of human NBS-1 (amino acid residues 3-79 of SEQ ID NO:2) with the pyrin domains of pyrin (SEQ ID NO:7), CARD-5 (SEQ ID NO:8), and CARD-7 (SEQ ID NO:9).
  • a consensus pyrin domain sequence (SEQ ID NO: 10) is shown above the alignment.
  • Figures 8A-8H each depict an alignment of individual leucine rich repeats within the LRR domain of NBS-1 ((amino acids 726-752 of SEQ ID NO:2 ( Figure 8 A), amino acids 782-809 of SEQ ID NO:2 ( Figure 8B), amino acids 811-838 of SEQ ID NO:2 ( Figure 8C), amino acids 839-866 of SEQ ID NO:2 ( Figure 8D), amino acids 868-895 of SEQ ID NO:2 ( Figure 8E), amino acids 896-923 of SEQ ID NO:2 ( Figure 8F), amino acids 925-952 of SEQ ID NO:2 ( Figure 8G), and amino acids 953-979 of SEQ ID NO:2 ( Figure 8H)) with a consensus LRR (SEQ ID NO: 12) derived from a hidden Markov model.
  • SEQ ID NO: 12 consensus LRR
  • HMMs can be used to do multiple sequence alignment and very sensitive database searching, using statistical descriptions of a sequence family's consensus. Information on HMM searches is available, for example, on the Internet at www.hmmr.wustl.edu.
  • a single letter amino acid designation on the line between the NBS-1 sequence and the HMM-generated consensus sequence indicates an exact match between the two.
  • a "+" on this middle line indicates a conservative substitution at the particular residue of NBS-1.
  • a cDNA encoding human PYRJN-1 was identified by searching a proprietary cDNA sequence database with a sequence encoding the pyrin domain of NBS-1. This search led to the identification of a 3.8-kilobase cDNA (clone jthPa091c07tl) from a human placenta library encoding a protein that was named PYRIN-1. This protein is also referred to as PYRIN-containing Apafl -like protein 1 (PYPAF-1).
  • Figures 4A-4E depict the sequence of a 3857 nucleotide cDNA (SEQ ID NO:4) which includes a predicted open reading frame (SEQ ID NO:6; nucleotides 141-3240 of SEQ ID NO:4) encoding a 1034 amino acid human PYRIN-1 protein (SEQ ID NO:5).
  • Human PYRIN-1 is predicted to be an intracellular protein having a predicted molecular mass of 118 kDa. The predicted amino acid sequence of human PYRIN-1 was compared to amino acid sequences of known proteins and various motifs were identified.
  • the 1034 amino acid human PYRJN-1 protein includes three N-glycosylation sites (e.g., about amino acid residues 654-657, 911-914, and 950-953 of SEQ ID NO:5); four cAMP- and cGMP-dependent protein kinase phosphorylation sites (e.g., about amino acid residues 164-167, 290-293, 592-595, and
  • SEQ ID NO:5 amino acid residues 448-449, 533-534, 559-560, 606-607, 815-816, 823-824, 929-930, 934-935, 962-963, and 997-998 of SEQ ID NO:5).
  • Figure 5 depicts a hydropathy plot of human PYRIN-1. Relatively hydrophobic residues are above the dashed horizontal line, and relatively hydrophilic residues are below the dashed horizontal line. Potential N-glycosylation sites (Ngly) and cysteine residues are indicated by short vertical lines just below the hydropathy trace.
  • FIG. 6 A plot showing the predicted structural features of human PYRIN-1 is presented in Figure 6. This figure shows the predicted alpha regions (Garnier-Robson and Chou-Fasman), the predicted beta regions (Garnier-Robson and Chou-Fasman), the predicted turn regions
  • a pyrin domain (about amino acids 1-90 of SEQ ID NO:5) a nucleotide binding site (NBS; about amino acid residues 263-357 of SEQ ID NO:5) and nine leucine rich repeats (LRRs; about amino acids residues 740-767, 769-796, 797-821, 826-849, 854-878, 883-906, 911-935, 940- 967, and 968-991 of SEQ ID NO:5) which form a LRR domain (about amino acids 740-991 of SEQ ID NO:5).
  • NSS nucleotide binding site
  • LRRs nine leucine rich repeats
  • kinase la domain (about amino acids 224-233 of SEQ ID NO:5)
  • kinase 2 domain (Walker B box)
  • kinase 3a domain (about amino acids 344-355 of SEQ ID NO:5).
  • An expanded NBS domain encompasses amino acids 219-434 of SEQ ID NO:5.
  • NBS domain belongs to the NACHT subfamily of NTPases and contains all seven signature motifs, including the P-loop and the Mg 2+ -binding site (Koonin et al. (2000) Trends Biochem. Sci. 25:223-224).
  • the seven signature motifs are located a amino acids 219-241, 248-278, 282-305, 326-351, 402-422, 489-504, and 515-534 of SEQ ID NO:5.
  • Figure 9A depicts an alignment of amino acids 1-82 of human PYRIN-1 (amino acid residues 1-82 of SEQ ID NO:5) with the pyrin domains of pyrin (SEQ ID NO:7), CARD-5 (SEQ ID NO:8), and CARD-7 (SEQ ID NO:9).
  • a consensus pyrin domain sequence (SEQ ID NO:l 1) is shown above the alignment.
  • Figure 9B depicts an alignment of amino acids 1-90 of human PYRIN-1 (amino acids 1-90 of SEQ ID NO:5 with the pyrin domains of pyrin (33% identity), CARD-7 (24% identity), ASC (25% identity), NBS-1 (24% identity), and POP-1 (28% identity).
  • Figures 10A-10I each depict an alignment of individual leucine rich repeats within the LRR domain of PYRIN-1 ((about amino acids 740-767 of SEQ ID NO:5 ( Figure 10A), amino acids 769-796 of SEQ ID NO:5 ( Figure 10B), amino acids 797-821 of SEQ ID NO:5 ( Figure 10C), amino acids 826-849 of SEQ ID NO:5 ( Figure 10D), amino acids 854-878 of
  • a search ofthe HTG genomic database identified a single BAC clone, RPl 1-433K2, containing the partial genomic sequence of PYRIN-1. This BAC clone maps to chromosome 1 at q44.
  • ASC is a small protein with an N-terminal PYRIN domain that also contains a C-terminal CARD domain (Masumoto et al. (1999) J. Biol. Chem. 274:33835).
  • ASC is also called CARD-5 (CARD-5 is described in U.S. Patent Application No. 09/841,879, filed April 24, 2001, U.S. Patent Application No. 09/728,721, filed December 1, 2000, U.S. Patent Application No.
  • pCMV-PYRIN-1-PYRIN/BD and pCMV-ASC- P YRIN/AD plasmids were constructed by inserting the PYRIN domains of PYRIN- 1 (residues 1-116) and ASC (residues 1-110) into pCMV-BD and pCMV-AD vectors, respectively (Stratagene; La Jolla, CA).
  • a plasmid expressing the CARD domain of ASC fused to the activation domain of NF-kB was prepared as described previously (Bertin et al. (2001) J. Biol. Chem. 276:11877-1 1882).
  • the plasmids were introduced into 293T cells transfected with the mammalian two- hybrid reporter construct pFR-Luc firefly reporter (Stratagene) or pRL-TK Renilla reporter (Promega).
  • the PYRIN domain of PYRIN-1 fused to the DNA-binding domain of GAL4 was screened against the PYRIN and CARD domains of ASC fused to the activation domain of murine NF-kB. After 24 h, cells were collected and assayed for relative luciferase activity as a measure of protein-protein interaction using the Dual-Luciferase reporter assay system
  • pCMV- PYRIN-l-PYRIN/BD and pCMV-ASC-CARD/AD plasmids were constructed by inserting amino acid 1 - 116 of PYRIN- 1 and the CARD domain of ASC (residues 92- 195) into pCMV-BD and pCMV-AD, respectively.
  • These mammalian two-hyrbid assays demonstrated that the PYRIN domain of PYRIN-1 interacts with the PYRIN domain of ASC, resulting in a 16-fold increase in relative luciferase activity.
  • Co-localization studies were performed to further examine the interactions between PYRIN-1 and ASC. These studies were carried out by expressing HA-tagged PYRIN-1 and FLAG-tagged ASC in Vero cells using recombinant adenoviruses, and then detecting the proteins using a mixture of anti-HA and anti-FLAG antibodies. Plasmids expressing either PYRIN-1 with a C-terminal FLAG epitope or ASC with a C-terminal HA epitope were constructed using pCMV-Tag 4a (Stratagene) and pCI (Promega), respectively.
  • PYRIN-1 and ASC When expressed alone, PYRIN-1 and ASC exhibited a distinct pattern of cellular localization. Whereas ASC localized to speck-like structures (Masumoto et al. (1999) J. Biol. Chem. 274:33835-33838), PYRIN-1 showed a cytoplasmic distribution that excluded the nucleus. However, when the two proteins were expressed in the same cell, PYRIN-1 was found to co-localize with the ASC speck-like structures. This finding confirms the interaction of PYRIN-1 with ASC previously observed by mammalian two-hybrid analysis and suggests that PYRIN-1 is recruited to a cytoplasmic signaling complex with ASC. Additional co-localization studies were carried out using FLAG-tagged PYRIN- 1 and
  • Plasmids expressing either a PYRI ⁇ -1 truncation mutant lacking the LRR domain (PYRI ⁇ -1 ⁇ LRR; residues 1-739) with a C-terminal FLAG epitope or ASC with a C-terminal HA epitope were constructed using pCI (Promega).
  • FLAG-tagged PYPAF1 and HA-tagged ASC were expressed in 293T embryonic kidney cells and detected using a mixture of anti-HA and anti-FLAG antibodies. When expressed alone, the two proteins exhibited a distinct pattern of cellular localization. Whereas ASC localizes to cytoplasmic punctate structures, full-length PYRI ⁇ -1 (PYRIN-1 - FL) showed a broad cytoplasmic distribution that excluded the nucleus.
  • PYRIN- 1-FL was found to co-localize with ASC.
  • PYRIN- 1 ⁇ PYRIN N-terminal PYRIN domain
  • PYRIN- 1 ⁇ LRR C-terminal LRRs
  • P YRIN- 1 ⁇ P YRIN failed to co-localize with the ASC punctate structures, demonstrating that the PYRIN domain of PYRJN-1 is necessary for recruitment.
  • PYRIN- 1 ⁇ LRR co-localized with ASC indicating that the C-terminal LRRs of PYRIN-1 were dispensable for recruitment.
  • PYRIN-1 Activates ASC Resulting in Increased NF-kB Activity
  • NF-kB activity assay described previously (Wang et al. (2001) J. Biol. Chem. 276:21405-21409). Briefly, 293T cells transfected with pNF-kB luciferase reporter (Stratagene), a transfection efficiency control pRL-TK Renilla reporter (Promega), and expression plasmids. Cells were harvested and firefly and Renilla luciferase activities were determined using the Dual-Luciferase reporter assay system (Promega).
  • NF-kB signaling occurred through the IKK complex because dominant-negative versions of IKK- ⁇ and IKK-2 blocked the ability of PYRIN-1 to synergistically activate NF- kB Fig. 26, lanes 3 and 4).
  • the N- terminal PYRIN domain of PYRIN-1 was essential for NF-kB signaling, since deletion of this domain (PYRIN- 1 ⁇ P YRIN) eliminated the synergistic induction of NF-kB activity (Fig. 15, lane 6).
  • Fig. 17 is a graph depicting the results of a PYRIN-1 mRNA expression assay in various immune system cells. As can be seen from these results, PYRIN- 1 is expressed at a higher level in CD8+ cells, CDl 1 b+ cells, MC cells treated with LPS, MC cells treated with
  • IgE IgE, and certain other cell types.
  • Figs. 18 and 19 depict the results of PYRIN-1 expression assays in two different murine models of rheumatoid arthritis as can be seen from these results, PYRIN-1 is elevated in rheumatoid arthritis, suggesting that inhibitors of PYRIN-1 expression or activity could be used to treat arthritis.
  • PYRIN-1 is an Apoptotic Signaling Molecule
  • PYRIN-containing proteins have been proposed to function in apoptotic signaling. Accordingly, the ability of PYRIN-1 to induce apoptosis when expressed in cells was investigated.
  • Adenoviruses expressing either PYRJN-1 or ASC were generated as described previously (Geddes et al. (2001) Biochem. Biophys. Res. Commun. 284:77-82).
  • Vero cells were transfected with recombinant adenovirus (20 plaque forming units per cell) expressing either KGFP or PYRIN- 1/K GFP with or without z-VAD- fmk (100 ⁇ M) and fixed at 56 h.
  • the nuclei were then stained with Hoescht 33342 and the percentage of apoptotic versus healthy nuclei in transfected cells was determined. Levels of apoptosis were determined as described previously (Geddes et al. (2001) supra).
  • a mammalian two-hybrid screen to determine whether ASC interacts with caspase-1, a CARD-containing caspase involved in apoptosis and cytokine processing was performed using caspase- 1 -CARD/BD to screen a panel of individual CARD domains.
  • the panel of CARD domains used for the mammalian two- hybrid screen and the plasmids expressing Apafl and caspase-1 were described previously (Bertin et al. (2001) supra, Wang et al. (2001) supra; Zou et al. (1997) Cell 90:405-413; Geddes et al. (2001) supra).
  • 293T cells were transfected with pCMV/AD and pCMV/BD plasmids, pFR-Luc firefly reporter (Stratagene), and, as a transfection efficiency control, pRL-TK Renilla reporter (Promega). Cells were harvested and firefly and Renilla luciferase activities were determined using the Dual-Luciferase reporter assay system (Promega).
  • the relative binding ofthe CARD domain caspase-1 to the CARD domains of various CARD domain-containing proteins was assessed as described above, and the results of this analysis are presented in Figure 12.
  • the CARD domain of caspase-1 was found to interact selectively with the CARD domain of ASC resulting in a 24-fold activation of luciferase activity.
  • PYRIN-1 may function in a manner analogous to other NBS/LRR family members and transmit upstream signals to the activation of ASC and other molecules recruited to the signaling complex. Activation of ASC by PYRIN-1 may occur through an induced- proximity mechanism analogous to the activation of caspase-9 by Apafl (Salvesen and Dixit, (1999) Proc. Nat'l Acad. Sci USA 96:10964). The restricted expression of PYRIN-1 to immune cells indicates a role for this protein and its binding-partners in inflammatory signaling.
  • caspase-1 also coordinates signaling pathways that regulate apoptosis and/or the processing of pro- inflammatory cytokines.
  • ASC has been identified recently as a signaling partner of pyrin, a protein involved in a rare inflammatory disorder known as familial Mediterranean fever (Richards et al. (2001) J Biol. Chem., In Press).
  • familial Mediterranean fever familial Mediterranean fever
  • PYRIN-1 maps to chromosome lq44, a locus associated with Muckle-Wells syndrome and familial cold urticaria, two genetically determined inflammatory disorders that are similar to Mediterranean fever (Cuisset et al. (1999) Am. J. Hum. Genet. 65:1054; Hoffman et al. (2000) Am. J. Hum. Genet. 66:1693; McDermott et al. (2000) Arthritis Rheum. 43:2034; Hoffman (2001) Nat. Genet. 29:301).
  • PYRI ⁇ -1 activity or expression e.g., alterations caused by mutations in the PYRI ⁇ -1 gene could be associated with the deregulation of inflammatory signaling and the onset of these hereditary fever syndromes, and factors which increase PYRI ⁇ -1 activity can be used to treat these disorders
  • TABLE 1 Summary of Human NBS-1 and Human PYRIN-1 Sequence Information
  • a plasmid containing a encoding human NBS-1 (p ) was deposited with the
  • NBS-1 and PYRIN-1 are members of a family of molecules (NBS-1 and PYRIN-1 families, respectively) having certain conserved structural and functional features.
  • family when referring to the protein and nucleic acid molecules ofthe invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain and having sufficient amino acid or nucleotide sequence identity as defined herein.
  • family members can be naturally occurring and can be from either the same or different species.
  • a family can contain a first protein of human origin and a homologue of that protein of murine origin, as well as a second, distinct protein of human origin and a murine homologue of that protein.
  • Members of a family may also have common functional characteristics.
  • Preferred NBS-1 or PYRIN-1 polypeptides ofthe present invention include an amino acid sequence sufficiently identical to one or more ofthe following domains: a pyrin domain, and NBS domain, and a LRR domain.
  • the term "sufficiently identical" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity.
  • a sufficient or minimum number of identical or equivalent e.g., an amino acid residue which has a similar side chain
  • amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity.
  • amino acid or nucleotide sequences which contain a common structural domain having about 65%o identity, preferably 75%) identity, more preferably 85%, 95%, or 98%) identity are defined herein as sufficiently identical.
  • NBS-1 or PYRIN-1 activity refers to an activity exerted by a NBS-1 or PYRIN-1 protein, polypeptide or nucleic acid molecule on a NBS-1 or PYRIN-1 responsive cell as determined in vivo, or in vitro, according to standard techniques.
  • NBS-1 or PYRIN-1 may act as a pro-apoptotic protein or an anti-apoptotic protein (i.e., it might act to decrease or increase apoptosis).
  • a NBS-1 or PYRIN-1 activity can be a direct activity, such as an association with or an enzymatic activity on a second protein or an indirect activity, such as a cellular signaling activity mediated by interaction ofthe NBS-1 or PYRIN-1 protein with a second protein.
  • a NBS-1 or PYRIN-1 activity can include at least one or more of the following activities: (i) the ability to interact with proteins in an apoptotic or inflammatory signaling pathway, e.g., ASC and/or caspase-1; (ii) the ability to interact with a NBS-1 or PYRIN-1; (iii) the ability to bind to and/or hydrolyze a nucleotide, e.g., ATP or GTP; (iv) the ability to interact with an intracellular target protein; (v) the ability to interact, directly or indirectly, with one or more proteins having a pyrin domain, a CARD domain, or other domain associated with apoptotic and/or inflammatory signaling; (vi) the ability to modulate, directly or indirectly, the activity of a caspase, e.g., caspase-9, caspase-4, caspase-1, and caspase-5; (vii) the ability to induce the activity of caspase-1 ; (i) the
  • a PYRJN-1 activity can include: (i) the ability to interact with ASC, e.g., via their respective pyrin domains; (ii) the ability to increase ASC-dependent NF- kB activity; (iii) the ability to increase apoptosis; (iv) the ability to increase caspase-mediated apoptosis or inflammation; (v) the ability to activate ASC; (vi) the ability to increase ASC- dependent caspase-1 activity; and (vii) the ability to transmit a pro-apoptotic signal to ASC.
  • ASC may interact with other pyrin domain-containing proteins in addition to PYRIN-1 , e.g., PYRIN-2, 3, 5, 6, 7, 8, 10, and 11 (described in U.S. Serial No. 10/066,521, filed January 31 , 2002, hereby incorporated by reference).
  • NBS-1 and PYRIN-1 nucleic acids and polypeptides are expected to be useful in the modulation of stress- related, apoptotic and inflammatory responses, e.g., for the treatment of apoptotic and inflammatory disorders.
  • NBS-1 and PYRIN-1 nucleic acids and polypeptides are expected to be useful in the diagnosis of apoptotic and inflammatory disorders as well as in screening assays which can be used to identify compounds which can be used to modulate stress-related, apoptotic and inflammatory responses.
  • R proteins cytoplasmic plant proteins involved in response to plant pathogens
  • R proteins have both an NBS domain and an LRR domain.
  • R proteins are involved in both a rapid defense response (hypersensitive response) and more long-term nonspecific resistance (systemic acquired resistance).
  • the hypersensitive response involves cell and tissue death that is localized to the site of infection.
  • the LRR domains of R proteins are believed to recognize and bind to pathogen proteins, triggering defensive responses.
  • Many R proteins have an amino terminal effector domain (e.g., a TIR domain or a leucine zipper domain) that is thought to play a role in downstream signaling of events triggered by infection and, possibly, other stresses.
  • the R proteins have some structural similarity to APAF-1, a protein which mediates between Bcl-2, a negative regulator of apoptosis, and caspases, which are the proteases directly responsible for the degradation of cellular proteins that leads to the morphological changes seen in cells undergoing apoptosis.
  • APAF-1 has a CARD domain, functionally analogous to the effector domain of R proteins, an NBS domain, and a WD-40 domain, functionally analogous to the LRR domain of R proteins.
  • CARD-4, CARD-7, and CARD- 12 each have an NBS domain and an LRR domain as well as a CARD domain (detailed information concerning CARD-4, CARD-7, and CARD- 12 can be found in U.S. Application Serial No. 09/245,281, filed February 5, 1999, U.S. Application Serial No. 09/207,359, filed December 8, 1998, U.S. Application Serial No. 09/099,041, filed June 17, 1998, U.S. Application Serial No. 09/019,942, filed February 6, 1998, U.S. Application Serial No. 09/428,252, filed October 27, 1999, and U.S. Application Serial No. 60/161,822, filed October 27, 1999, all of which are incorporated herein by reference).
  • the CARD domain which is present in a number of apoptotic signaling molecules, is an effector domain that thought to be involved in homophilic protein-protein interactions, e.g., with downstream CARD-containing signaling molecules.
  • the CARD domain of CARD-4 interacts with the CARD domain of RICK (RIP2, CARDIAK), a serine-threonine kinase that activates NF- ⁇ B signaling pathways.
  • RICK RIP2, CARDIAK
  • Other proteins structurally related to NBS-1 and PYRIN-1 include NBS-2, NBS-3,
  • NBS-4, and NBS-5 each of which contains an NBS domain.
  • NBS-2, NBS-3, and NBS-5 contain LRR domains and NBS-2 and NBS-3 contain pyrin domains.
  • Detailed information concerning NBS-2, NBS-3, NBS-4, and NBS-5 can be found in U.S. Application Serial No. 60/201,464, filed May 3, 2000, which is incorporated herein by reference.
  • an NBS domain includes a kinase la domain (P-loop), a kinase 2 domain
  • An LRR domain usually is composed of several leucine rich repeats.
  • NBS-1 and PYRIN-1 interacts with an upstream signaling molecule that is associated with stress, infection, or inflammation. This interaction triggers a conformational change in NBS-
  • PYRIN-1 that exposes an effector domain, e.g., the pyrin domain of NBS-1.
  • the exposed effector domain then mediates interaction with a downstream signaling molecule or molecules to transmit a stress-related, apoptotic or inflammatory signal.
  • the conformational change is dependent upon binding and/or hydrolysis of a nucleotide triphosphate (ATP or GTP) bound to the NBS domain.
  • ATP nucleotide triphosphate
  • NBS-1 and PYRIN-1 molecules are useful as modulating agents in regulating a variety of cellular processes including inflammation and apoptosis.
  • the molecules are also useful in the identification of agent for the modulation of inflammation and apoptosis.
  • the invention encompasses methods of diagnosing and treating patients who are suffering from a disorder associated with an abnormal level or rate (undesirably high or undesirably low) of apoptotic cell death, abnormal activity of stress-related pathways ofthe endoplasmic reticulum (ER), abnormal activity ofthe Fas/APO-1 receptor complex, abnormal activity ofthe TNF receptor complex, abnormal activity of NF-kB, or abnormal activity of a caspase by administering a compound that modulates the expression of NBS-1 or PYRJN-1 (at the DNA, mRNA or protein level, e.g., by altering mRNA splicing) or by altering the activity of NBS-1 or PYRIN-1.
  • Examples of such compounds include small molecules, antis
  • NBS-1 or PYRIN-1 and compounds that modulate the expression or activity of NBS-1 or PYRIN-1 can be used to treat or diagnose such disorders.
  • These disorders include cancer (particularly follicular lymphomas, chronic myelogenous leukemia, melanoma, colon cancer, lung carcinoma, carcinomas associated with mutations in p53, and hormone-dependent tumors such as breast cancer, prostate cancer, and ovarian cancer).
  • Such compounds can also be used to treat viral infections (such as those caused by herpesviruses, poxviruses, and adenoviruses).
  • an autoimmune disorder can be caused by an undesirably low level of apoptosis.
  • NBS-1 or PYRIN-1 and modulators of NBS-1 or PYRIN-1 activity or expression can be used to treat autoimmune disorders (e.g., systemic lupus erythematosis, immune-mediated glomerulonephritis, and arthritis).
  • NBS-1 or PYRIN-1 and modulators of NBS-1 or PYRIN-1 expression or activity can be used to treat or diagnose such disorders.
  • a wide variety of neurological diseases are characterized by the gradual loss of specific sets of neurons. Such disorders include Alzheimer's disease,
  • Parkinson's disease amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, spinal muscular atrophy, Huntington's disease, and various forms of cerebellar degeneration.
  • ALS amyotrophic lateral sclerosis
  • retinitis pigmentosa spinal muscular atrophy
  • Huntington's disease various forms of cerebellar degeneration.
  • the cell loss in these diseases does not induce an inflammatory response, and apoptosis appears to be the mechanism of cell death.
  • a number of hematologic diseases are associated with a decreased production of blood cells. These disorders include anemia associated with chronic disease, aplastic anemia, chronic neutropenia, and the myelodysplastic syndromes. Disorders of blood cell production, such as myelodysplastic syndrome and some forms of aplastic anemia, are associated with increased apoptotic cell death within the bone marrow.
  • disorders could result from the activation of genes that promote apoptosis, acquired deficiencies in stromal cells or hematopoietic survival factors, or the direct effects of toxins and mediators of immune responses.
  • Two common disorders associated with cell death are myocardial infarctions and stroke. In both disorders, cells within the central area of ischemia, which is produced in the event of acute loss of blood flow, appear to die rapidly as a result of necrosis. However, outside the central ischemic zone, cells die over a more protracted time period and morphologically appear to die by apoptosis.
  • Additional diseases associated with an undesirably high rate of apoptosis include: ischemic and hypoxic brain injury, traumatic and excitotoxic brain damage, neuronal transplantation, acute bacterial meningitis, kidney ischemia/reperfusion injury, and liver disease.
  • NBS-1 or PYRIN-1 and modulators of NBS-1 or PYRIN-1 may therefore be useful in treating and diagnosing these conditions.
  • HIV human immunodeficiency virus
  • NBS-1 or PYRIN-1 polypeptides can be used to treat inflammatory disorders and immune system disorders, e.g., by interfering with or inhibiting NF- ⁇ B activity that is stimulated by PYRIN- 1.
  • Disorders include inflammatory disorders include such as inflammatory bowel disorders,
  • rohn's disease Crohn's disease, ulcerative colitis, reactive arthritis, rheumatoid arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, respiratory inflammatory diseases and disorders, such as asthma and chronic obstructive pulmonary disease, gastrointestinal allergies, including food allergies, eosinophilia, conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as helminthic (e.g., leishmaniasis), certain viral infections, including HIV, and bacterial infections, including tuberculosis and lepromatous leprosy.
  • helminthic e.g., leishmaniasis
  • Such disorders can be treated by interfering with PYRIN-1 -mediated pro-inflammatory activity.
  • Other inflammatory disorders that might be treated by decreasing PYRIN-1 -mediated NF- ⁇ B activity include, e.g., bacterial infection, psoriasis, septicemia, cerebral malaria, inflammatory bowel disease, arthritis (e.g., rheumatoid arthritis, osteoarthritis) colitis (e.g., idiopathic ulcerative colitis and pseudomembranous colitis)
  • Ischemia is often accompanied by inflammation that causes cell death. Because
  • NBS-1 and PYRIN-1 are expected to play a role in stress-related response, inflammation and apoptosis
  • NBS-1 or PYRIN-1 polypeptides, nucleic acids, and modulators of NBS-1 or PYRIN-1 expression or activity can be used to treat cells death accompanying inflammatory responses triggered by ischemia. Invasive infection with Gram-negative bacteria and Gram-positive bacteria often results in septic shock.
  • NBS-1 and PYRIN-1 may recognize and bind components of Gram- negative bacteria and Gram-positive bacteria or other infectious agents (e.g., intracellular parasites), triggering an inflammatory response.
  • NBS-1 and PYRIN-1 may play a role in innate immune system responses that is similar to that of Toll-like receptor 2 (TLR2), a receptor which has some structural similarity to plant R proteins and IL-1R.
  • TLR2 is a signaling receptor that, in association with CD 14, is activated by LPS in a response that requires LPS-binding protein.
  • the interaction of TLR2 with LPS leads to TLR2 oligomerization and recruitment of IRAK (Yang et al. (1998) Nature 395:284-88; Yang et al (1999) J Immunol. 163:639-43; and Yoshimura et al. (1999) J. Immunol. 163:105).
  • TLR2 is thought to be a direct mediator of signaling by LPS. TLR2 is also thought to mediate cell activation induced by peptidoglycan and lipoteichoic acid, the main stimulatory components of Gram-positive bacteria (Schwandner et al. (1999) J. Biol. Chem. 274:17406- 09).
  • Modulators of PYRIN-1 activity e.g., activators of PYRJN-1 activity or expression can be used to treat Muckle-Wells syndrome and familial cold urticaria. Modulators of PYRIN-1 activity may be particularly useful for treating arthritis, e.g., rheumatoid arthritis.
  • NBS-1 or PYRIN-1 polypeptides, nucleic acids, and modulators of NBS-1 or PYRJN-1 expression or activity can be used to treat septic shock and other disorders associated with an innate immune response.
  • NBS-1 or PYRIN-1 may bind to a component of an intracellular infectious agent or a component of an infectious agent that is brought into a cell expressing NBS-1 or PYRIN-1, e.g., a component that enters a cell through a receptor or is expressed by a viral gene.
  • NBS-1 or PYRIN-1 polypeptides, nucleic acids, and modulators of NBS-1 or PYRIN-1 expression or activity can be used to treat disorders of cell signaling and disorders of tissues in which NBS-1 or PYRIN-1 is expressed.
  • nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more ofthe following methods: a) screening assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology), c) predictive medicine
  • a NBS-1 or PYRIN-1 protein interacts with other cellular proteins and can thus be used for (i) regulation of cellular proliferation; (ii) regulation of cellular differentiation; and (iii) regulation of cell survival.
  • the isolated nucleic acid molecules ofthe invention can be used to express NBS-1 or PYRIN-1 protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NBS-1 or PYRIN-1 mRNA (e.g., in a biological sample) or a genetic lesion in a NBS-1 or PYRIN-1 gene, and to modulate NBS-1 or PYRIN- 1 activity.
  • the NBS-1 or PYRIN-1 proteins can be used to screen drugs or compounds which modulate the NBS-1 or PYRIN-1 activity or expression as well as to treat disorders characterized by insufficient or excessive production of NBS-1 or PYRIN-1 protein or production of NBS-1 or PYRIN-1 protein forms which have decreased or aberrant activity compared to NBS-1 or PYRJN-1 wild type protein.
  • the anti-NBS-1 or PYRIN-1 antibodies of the invention can be used to detect and isolate NBS-1 or PYRIN-1 proteins and modulate NBS-1 or PYRIN-1 activity.
  • This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.
  • the invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to NBS-1 or PYRIN-1 proteins or biologically active portions thereof or have a stimulatory or inhibitory effect on, for example, NBS-1 or PYRIN-1 expression or NBS-1 or PYRIN-1 activity.
  • modulators i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to NBS-1 or PYRIN-1 proteins or biologically active portions thereof or have a stimulatory or inhibitory effect on, for example, NBS-1 or PYRIN-1 expression or NBS-1 or PYRIN-1 activity.
  • modulators i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules
  • screening assays are screening to identify molecules that prevent the interaction of NBS-1 or PYRIN-1 with another protein and screening to identify a competitive inhibitor ofthe binding ofa nucleotide to the nucleotide binding site of NBS-1 or PYRIN-1.
  • Such assays can employ full-length NBS-1 or PYRIN-1 or a portion of NBS-1 or PYRIN-1, e.g., a domain define herein.
  • Screening assays can be used to identify molecules which modulate a NBS-1 or PYRJN-1 mediated increase in transcription of genes having an AP-1 or NF- ⁇ B binding site. For example, expression of a reporter gene under the control of NF- ⁇ B (or AP-1) is measured in the presence and absence of a candidate molecule and in the presence and absence of NBS-1 or PYRIN-1 to identify those molecules which alter expression ofthe reporter in a NBS-1 or PYRIN-1 dependent manner. In addition, screening assays can be used to identify molecules that modulate a NBS-1 or PYRIN-1 mediated increase in CHOP phosphorylation.
  • the expression of a reporter gene under the control of CHOP is measured in the presence and absence of a candidate small molecule and in the presence and absence of NBS-1 or PYRIN-1 to identify those molecules that alter expression ofthe reporter in a NBS-1 or PYRIN-1 dependent manner.
  • a screening assay can be carried out to identify molecules which modulate the NBS-1 or PYRJN-1 mediated increase in CHOP phosphorylation.
  • CHOP phosphorylation is measured in the presence and absence ofa candidate molecule and in the presence and absence of NBS-1 or PYRJN-1.
  • Phosphorylation of CHOP can be measured using an antibody which binds to phosphorylated CHOP, but not to non-phosphorylated CHOP.
  • Molecules that bind to and/or alter the activity of an NBS domain of NBS-1 or PYRIN-1 may be useful for modulating the activity of NBS-1 or PYRIN-1.
  • molecules can be tested for their ability to modulate, e.g., antagonize, the hydrolysis of an
  • NTP e.g., ATP
  • NBS domain or a fragment of an NBS domain such as an NBS motif described herein
  • Methods of detecting the hydrolysis of a NTP by a protein containing a nucleotide-binding site are described in, for example, Li et al. (1996) J. Biol. Chem. 271 :28463-28468 and Gadsby et al. (1999) Physiol. Rev. 79:S77-S107.
  • a purified protein containing an NBS domain of NBS-1 or PYRIN-1 can be evaluated for its ability to mediate NTPase activity in vitro.
  • the assay can be performed in the presence of a test compound to determine the ability of the test compound to modulate the NTPase activity ofthe purified protein.
  • the purified protein used in an NTPase activity assay can be a variant or a fragment of NBS-1 or PYRIN-1, and the assay can be performed to determine the NTPase activity ofthe fragment or variant.
  • an NBS domain can be assayed for its ability to hydrolyze ATP.
  • ATPase activity can measured as the production of [ ⁇ -PJADP from [ ⁇ -P]ATP, using polyethyleneimine-cellulose chromatography for separation ofthe nucleotides.
  • the assay can be carried out in a 15 ⁇ l reaction mixture containing 50 mM Tris, 50 mM NaCl, pH 7.5, 2 mM MgCl 2 , 10% glycerol, 0.5 mM CHAPS, and 8 ⁇ Ci of [ ⁇ 32 -P]ATP. Reaction mixtures are incubated at 30°C and are stopped by the addition of 5 ⁇ l of 10%> SDS. One ⁇ l samples are spotted on a polyethyleneimine-cellulose plate and developed in 1 M formic acid, 0.5 M LiCl. The location and quantitation ofthe radiolabeled ATP and ADP can determined with a Molecular Dynamics Phosphorlmager. Data can be analyzed using the ImageQuant software package (Molecular Dynamics).
  • the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a NBS-1 or PYRIN-1 proteins or polypeptides or biologically active portions thereof.
  • the test compounds of the present invention can be obtained using any ofthe numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12:145).
  • an assay is one in which a polypeptide ofthe invention, or a biologically active portion thereof, is contacted with a test compound and the ability ofthe test compound to bind to the polypeptide determined. Determining the ability ofthe test compound to bind to the polypeptide can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding ofthe test compound to the polypeptide or biologically active portion thereof can be determined by detecting the labeled compound in a complex.
  • test compounds can be labeled with 125 1, 35 S, 14 C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting.
  • test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
  • Determining the ability ofthe test compound to modulate the activity of NBS-1 or PYRIN-1 or a biologically active portion thereof can be accomplished, for example, by determining the ability ofthe NBS-1 or PYRIN-1 protein to bind to or interact with a NBS-1 or PYRIN-1 target molecule.
  • a "target molecule” is a molecule with which a NBS-1 or PYRIN-1 protein binds or interacts in nature, for example, a molecule associated with the internal surface ofa cell membrane or a cytoplasmic molecule.
  • a NBS-1 or PYRIN-1 target molecule can be a non-NBS-1 or PYRIN-1 molecule or a NBS-1 or PYRIN- 1 protein or polypeptide ofthe present invention.
  • a NBS-1 or PYRIN-1 target molecule is a component of an apoptotic signal transduction pathway.
  • the target for example, can be a second intracellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with NBS-1 or PYRIN-1.
  • the target can be another protein having a pyrin domain (or a pyrin domain containing fragment thereof).
  • NBS-1 or PYRIN-1 target molecules include all proteins that bind to a NBS-1 or PYRIN-1 protein or a fragment thereof in a two-hybrid system binding assay which can be used without undue experimentation to isolate such proteins from cDNA or genomic two-hybrid system libraries.
  • the binding assays described in this section can be cell-based or cell free (described subsequently). Determining the ability ofthe NBS-1 or PYRJN-1 protein to bind to or interact with a
  • NBS-1 or PYRIN-1 target molecule can be accomplished by one ofthe methods described above for determining direct binding.
  • determining the ability ofthe NBS- 1 or PYRIN-1 protein to bind to or interact with a NBS-1 or PYRIN-1 target molecule can be accomplished by determining the activity ofthe target molecule.
  • the activity of the target molecule can be determined by detecting induction of a cellular second messenger
  • the target e.g., intracellular Ca , diacylglycerol, IP3, etc.
  • the target e.g., intracellular Ca , diacylglycerol, IP3, etc.
  • detecting catalytic/enzymatic activity ofthe target on an appropriate substrate detecting the induction of a reporter gene (e.g., a NBS-1 or PYRIN-1 -responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g. luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.
  • a reporter gene e.g., a NBS-1 or PYRIN-1 -responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g. luciferase
  • detecting a cellular response for example, cell survival, cellular differentiation, or cell proliferation.
  • the activity of a target molecule can be monitored by
  • genes induced by NBS-1 or PYRIN-1 expression can be identified by expressing NBS-1 or PYRJN-1 in a cell line and conducting a transcriptional profiling experiment wherein the mRNA expression patterns ofthe cell line transformed with an empty expression vector and the cell line transformed with a NBS-1 or PYRIN-1 expression vector are compared.
  • the promoters of genes induced by NBS-1 or PYRIN-1 expression can be operatively linked to reporter genes suitable for screening such as luciferase, secreted alkaline phosphatase, or beta-galactosidase and the resulting constructs could be introduced into appropriate expression vectors.
  • a recombinant cell line containing NBS-1 or PYRIN-1 and transfected with an expression vector containing a NBS-1 or PYRIN-1 responsive promoter operatively linked to a reporter gene can be used to identify test compounds that modulate NBS-1 or PYRIN-1 activity by assaying the expression ofthe reporter gene in response to contacting the recombinant cell line with test compounds.
  • NBS-1 or PYRIN-1 agonists can be identified as increasing the expression ofthe reporter gene and NBS-1 or PYRIN-1 antagonists can be identified as decreasing the expression ofthe reporter gene.
  • the ability of a test compound to modulate the activity of NBS-1 or PYRIN-1, or biologically active portions thereof can be determined by assaying the ability ofthe test compound to modulate NBS-1 or PYRIN-1 -dependent pathways or processes where the NBS-1 or PYRIN-1 target proteins that mediate the NBS-1 or PYRIN-1 effect are known or unknown.
  • NBS-1 or PYRIN-1 -dependent pathways or processes include, but are not limited to, the modulation of cellular signal transduction pathways and their related second messenger molecules (e.g., intracellular Ca 2+ , diacyl glycerol, IP3, cAMP etc.), cellular enzymatic activities, cellular responses (e.g., cell survival, cellular differentiation, or cell proliferation), or the induction or repression of cellular or heterologous mRNAs or proteins.
  • NBS-1 or PYRJN-1 -dependent pathways or processes could be assayed by standard cell-based or cell free assays appropriate for the specific pathway or process under study.
  • cells cotransfected with NBS-1 or PYRIN-1 and a NF- ⁇ B luciferase reporter gene could be contacted with a test compound and test compounds that block NBS-1 or PYRIN-1 activity could be identified by their reduction of NBS-1 or PYRIN-1 -dependent NF- ⁇ B pathway luciferase reporter gene expression.
  • Test compounds that agonize NBS-1 or PYRIN-1 would be expected to increase reporter gene expression.
  • NBS-1 or PYRIN-1 could be expressed in a cell line and the recombinant NBS-1 or PYRIN-1 -expressing cell line could be contacted with a test compound.
  • Test compounds that inhibit NBS-1 or PYRIN-1 activity could be identified by their reduction of NBS-1 or PYRIN-1 -depended NF- ⁇ B pathway stimulation as measured by the assay of a NF- ⁇ B pathway reporter gene, NF- ⁇ B nuclear localization, I ⁇ B phosphorylation or proteolysis, or other standard assays for NF- ⁇ B pathway activation known to those skilled in the art.
  • an assay ofthe present invention is a cell-free assay comprising contacting a NBS-1 or PYRIN-1 protein or biologically active portion thereof with a test compound and determining the ability ofthe test compound to bind to the NBS-1 or PYRIN-1 protein or biologically active portion thereof. Binding of the test compound to the NBS-1 or PYRIN-1 protein can be determined either directly or indirectly as described above.
  • a competitive binding assay includes contacting the NBS-1 or PYRIN-1 protein or biologically active portion thereof with a compound known to bind NBS-1 or PYRIN-1 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with a NBS-1 or PYRIN-1 protein, wherein determining the ability ofthe test compound to interact with a
  • NBS-1 or PYRIN-1 protein comprises determining the ability ofthe test compound to preferentially bind to NBS-1 or PYRIN-1 or biologically active portion thereof as compared to the known binding compound.
  • an assay is a cell-free assay comprising contacting NBS-1 or PYRIN-1 protein or biologically active portion thereof with a test compound and determining the ability ofthe test compound to modulate (e.g., stimulate or inhibit) the activity ofthe NBS-1 or PYRIN-1 protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of NBS-1 or PYRIN-1 can be accomplished, for example, by determining the ability ofthe NBS-1 or PYRIN-1 protein to bind to or interact with a NBS-1 or PYRIN-1 target molecule by one ofthe methods described above for determining direct binding.
  • determining the ability ofthe test compound to modulate the activity of NBS-1 or PYRIN-1 can be accomplished by determining the ability ofthe NBS-1 or PYRIN-1 protein to further modulate a NBS-1 or PYRIN-1 target molecule.
  • the catalytic/enzymatic activity ofthe target molecule on an appropriate substrate can be determined as previously described.
  • the cell-free assay comprises contacting the NBS-1 or PYRIN-1 protein or biologically active portion thereof with a known compound which binds NBS-1 or PYRIN-1 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with a NBS-1 or PYRIN-1 protein, wherein determining the ability ofthe test compound to interact with a
  • NBS-1 or PYRIN-1 protein comprises determining the ability ofthe NBS-1 or PYRIN-1 protein to preferentially bind to or modulate the activity of a NBS-1 or PYRIN-1 target molecule.
  • the cell-free assays ofthe present invention are amenable to use of either the soluble form or a membrane-associated form of NBS-1 or PYRIN-1.
  • a membrane-associated form of NBS-1 or PYRIN-1 refers to NBS-1 or PYRIN-1 that interacts with a membrane-bound target molecule.
  • non-ionic detergents such as n-octyl
  • NBS-1 or PYRJN-1 or its target molecule it may be desirable to immobilize either NBS-1 or PYRJN-1 or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both ofthe proteins, as well as to accommodate automation ofthe assay.
  • Binding of a test compound to NBS-1 or PYRIN- 1, or interaction of NBS-1 or PYRIN-1 with a target molecule in the presence and absence of a candidate compound can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes.
  • a fusion protein can be provided which adds a domain that allows one or both ofthe proteins to be bound to a matrix.
  • glutathione-S-transferase/NBS-1 or PYRIN-1 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or NBS-1 or PYRIN-1 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH).
  • glutathione sepharose beads Sigma Chemical; St. Louis, MO
  • glutathione derivatized microtitre plates which are then combined with the test compound or the test compound and either the non-adsorbed target protein or NBS-1 or PYRIN-1 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH).
  • the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above.
  • the complexes can be dissociated from the matrix, and the level of NBS-1 or PYRIN-1 binding or activity determined using standard techniques.
  • MYC or HA epitope tag NBS-1 or PYRJN-1 fusion proteins or MYC or HA epitope tag target fusion proteins can be adsorbed onto anti-MYC or anti-HA antibody coated microbeads or onto anti-MYC or anti-HA antibody coated microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or NBS-1 or PYRIN-1 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH).
  • the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above.
  • the complexes can be dissociated from the matrix, and the level of NBS-1 or PYRIN-1 binding or activity determined using standard techniques.
  • NBS-1 or PYRIN-1 or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
  • Biotinylated NBS-1 or PYRIN-1 target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
  • antibodies reactive with NBS-1 or PYRIN-1 or target molecules but which do not interfere with binding ofthe protein to its target molecule can be derivatized to the wells ofthe plate, and unbound target or protein trapped in the wells by antibody conjugation.
  • Methods for detecting such complexes include immunodetection of complexes using antibodies reactive with the NBS-1 or PYRIN-1 or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the NBS-1 or PYRJN-1 or a target molecule.
  • modulators of NBS-1 or PYRIN-1 expression are identified in a method in which a cell is contacted with a candidate compound and the expression ofthe NBS-1 or PYRIN-1 promoter, mRNA or protein in the cell is determined.
  • the level of expression of NBS-1 or PYRIN-1 mRNA or protein in the presence ofthe candidate compound is compared to the level of expression of NBS-1 or PYRIN-1 mRNA or protein in the absence ofthe candidate compound.
  • the candidate compound can then be identified as a modulator of NBS-1 or PYRIN-1 expression based on this comparison.
  • the candidate compound when expression of NBS-1 or PYRIN-1 mRNA or protein is greater (statistically significantly greater) in the presence ofthe candidate compound than in its absence, the candidate compound is identified as a stimulator of NBS-1 or PYRIN-1 mRNA or protein expression.
  • the candidate compound when expression of NBS-1 or PYRIN-1 mRNA or protein is less (statistically significantly less) in the presence ofthe candidate compound than in its absence, the candidate compound is identified as an inhibitor of NBS-1 or PYRIN-1 mRNA or protein expression.
  • the level of NBS-1 or PYRIN-1 mRNA or protein expression in the cells can be determined by methods described herein for detecting NBS-1 or PYRIN-1 mRNA or protein.
  • the activity ofthe NBS-1 or PYRIN-1 promoter can be assayed by linking the NBS-1 or PYRIN-1 promoter to a reporter gene such as luciferase, secreted alkaline phosphatase, or beta-galactosidase and introducing the resulting construct into an appropriate vector, transfecting a host cell line, and measuring the activity of the reporter gene in response to test compounds.
  • a reporter gene such as luciferase, secreted alkaline phosphatase, or beta-galactosidase
  • the NBS-1 or PYRIN-1 proteins can be used as
  • bait proteins in a two-hybrid assay (for a discussion of a mammalian two-hybrid assay, see e.g., Hosfield and Chang (1999) Strategies Newsletter 2(2):62-65) or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J Biol. Chem. 268:12046-12054; Bartel et al. (1993) Bio/Techniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and PCT Publication No.
  • NBS-1 or PYRIN-1 -binding proteins or "NBS-1 or PYRIN-1-bp"
  • NBS-1 or PYRIN-1-binding proteins bind to or interact with NBS-1 or PYRIN-1
  • Such NBS-1 or PYRIN-1 -binding proteins are also likely to be involved in the propagation of signals by the NBS-1 or PYRIN-1 proteins as, for example, upstream or downstream elements ofthe NBS-1 or PYRIN-1 pathway.
  • the two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains.
  • the assay utilizes two different DNA constructs.
  • the gene that codes for NBS-1 or PYRIN-1 is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4).
  • a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey" or "sample”) is fused to a gene that codes for the activation domain ofthe known transcription factor.
  • the DNA-binding and activation domains ofthe transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression ofthe reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with NBS-1 or PYRIN-1.
  • a reporter gene e.g., LacZ
  • the ability of a test compound to modulate the activity of NBS-1 or PYRIN-1, or a biologically active portion thereof can be determined by assaying the ability ofthe test compound to block the binding of NBS-1 or PYRIN-1 to its target proteins in a yeast or mammalian two-hybrid system assay. This assay could be automated for high throughput drug screening purposes.
  • NBS-1 or PYRIN-1 and a target protein could be configured in the reverse two-hybrid system (Vidal et al. (1996) Proc. Natl. Acad. Sci. USA 93:10321-6 and Vidal et al. (1996) Proc. Natl. Acad. Sci.
  • NBS-1 or PYRIN-1 interactors could be configured into two-hybrid system baits and used in two-hybrid screens to identify additional members of the NBS-1 or PYRIN-1 pathway.
  • the interactors of NBS-1 or PYRIN-1 interactors identified in this way could be useful targets for therapeutic intervention in NBS-1 or PYRIN-1 related diseases and pathologies and an assay of their enzymatic or binding activity could be useful for the identification of test compounds that modulate NBS-1 or PYRIN-1 activity.
  • This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.
  • the present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically.
  • diagnostic assays for determining NBS-1 or PYRIN-1 protein and/or nucleic acid expression as well as NBS-1 or PYRIN-1 activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NBS-1 or PYRJN-1 expression or activity.
  • a biological sample e.g., blood, serum, cells, tissue
  • the invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NBS-1 or PYRIN-1 protein, nucleic acid expression or activity. For example, mutations in a NBS-1 or PYRIN-1 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NBS-1 or PYRIN-1 protein, nucleic acid expression or activity.
  • Another aspect ofthe invention provides methods for determining NBS-1 or PYRIN- 1 protein, nucleic acid expression or NBS-1 or PYRJN-1 activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics").
  • Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype ofthe individual (e.g., the genotype ofthe individual examined to determine the ability of the individual to respond to a particular agent.)
  • Yet another aspect ofthe invention pertains to monitoring the influence of agents (e.g., drugs or other compounds) on the expression or activity of NBS-1 or PYRIN-1 in clinical trials.
  • An exemplary method for detecting the presence or absence of NBS-1 or PYRIN-1 in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NBS-1 or PYRJN-1 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NBS-1 or PYRIN-1 protein such that the presence of NBS-1 or PYRIN-1 is detected in the biological sample.
  • a compound or an agent capable of detecting NBS-1 or PYRJN-1 protein or nucleic acid e.g., mRNA, genomic DNA
  • An agent for detecting NBS-1 or PYRIN-1 mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NBS-1 or PYRIN-1 mRNA or genomic DNA.
  • the nucleic acid probe can be, for example, a full-length NBS-1 or PYRIN-1 nucleic acid, such as the nucleic acid of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250, 500, 750, 1000, 1250, or
  • An agent for detecting NBS-1 or PYRIN-1 protein can be an antibody capable of binding to NBS-1 or PYRIN-1 protein, preferably an antibody with a detectable label.
  • Antibodies can be polyclonal, or more preferably, monoclonal.
  • An intact antibody, or a fragment thereof e.g., Fab or F(ab')2
  • the term "labeled", with regard to the probe or antibody is intended to encompass direct labeling ofthe probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling ofthe probe or antibody by reactivity with another reagent that is directly labeled.
  • indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling ofa DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
  • biological sample is intended to include tissues, cells, biological fluids, and stool samples isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method ofthe invention can be used to detect NBS-1 or PYRIN-1 mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.
  • in vitro techniques for detection of NBS-1 or PYRIN-1 mRNA include Northern hybridizations and in situ hybridizations.
  • in vitro techniques for detection of NBS-1 or PYRIN-1 protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
  • In vitro techniques for detection of NBS-1 or PYRIN-1 genomic DNA include Southern hybridizations.
  • in vivo techniques for detection of NBS-1 or PYRJN-1 protein include introducing into a subject a labeled anti-NBS-1 or PYRIN-1 antibody.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • Stool samples may be analyzed using various in vitro techniques, including techniques directed to analysis of DNA, RNA, or protein in the sample (Machiels et al. (2000) BioTechniques 28:286-290).
  • the biological sample contains protein molecules from the test subject.
  • the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject.
  • a biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
  • the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NBS-1 or PYRIN-1 protein, mRNA, or genomic DNA, such that the presence of NBS-1 or PYRIN-1 protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NBS-1 or PYRIN-1 protein, mRNA or genomic DNA in the control sample with the presence of NBS-1 or PYRIN-1 protein, mRNA or genomic DNA in the test sample.
  • kits for detecting the presence of NBS-1 or PYRIN-1 in a biological sample can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of NBS-1 or PYRIN-1 (e.g., an immunological disorder).
  • the kit can comprise a labeled compound or agent capable of detecting NBS-1 or PYRJN-1 protein or mRNA in a biological sample and means for determining the amount of NBS-1 or PYRIN-1 in the sample (e.g., an anti-NBS-1 or PYRJN-1 antibody or an oligonucleotide probe which binds to DNA encoding NBS-1 or PYRIN-1, e.g., SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6).
  • Kits may also include instruction for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of NBS-1 or PYRIN-1 ifthe amount of NBS-1 or PYRIN-1 protein or mRNA is above or below a normal level.
  • the kit may comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to NBS-1 or PYRJN-1 protein; and, optionally, (2) a second, different antibody which binds to NBS-1 or PYRIN-1 protein or the first antibody and is conjugated to a detectable agent.
  • a first antibody e.g., attached to a solid support
  • a second, different antibody which binds to NBS-1 or PYRIN-1 protein or the first antibody and is conjugated to a detectable agent.
  • the kit may comprise, for example: (1) a oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a NBS-1 or PYRIN-1 nucleic acid sequence or (2) a pair of primers useful for amplifying a NBS-1 or PYRIN-1 nucleic acid molecule.
  • the kit may also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent.
  • the kit may also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate).
  • the kit may also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained.
  • Each component ofthe kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of NBS-1 or PYRJN-1.
  • the methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant NBS-1 or PYRIN-1 expression or activity.
  • the assays described herein such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NBS-1 or PYRIN-1 protein, nucleic acid expression or activity.
  • the prognostic assays can be utilized to identify a subject having or at risk for developing such a disease or disorder.
  • test sample refers to a biological sample obtained from a subject of interest.
  • a test sample can be a biological fluid (e.g., serum), cell sample, tissue, or stool sample.
  • Stool samples may be analyzed using various in vitro techniques, including techniques directed to analysis of DNA, RNA, or protein in the sample (Machiels et al. (2000) BioTechniques 28:286-290).
  • the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NBS-1 or PYRIN-1 expression or activity.
  • an agent e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
  • such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease NBS-1 or PYRJN-1 activity).
  • the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NBS-1 or PYRJN-1 expression or activity in which a test sample is obtained and NBS-1 or PYRIN-1 protein or nucleic acid is detected (e.g., wherein the presence of NBS-1 or PYRJN-1 protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NBS-1 or PYRIN-1 expression or activity).
  • the methods ofthe invention can also be used to detect genetic lesions or mutations in a NBS-1 or PYRIN-1 gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation.
  • the methods include detecting, in a sample of cells from the subject, the presence or absence ofa genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NBS-1 or PYRIN-1 -protein, or the mis-expression ofthe NBS-1 or PYRIN-1 gene.
  • such genetic lesions can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a NBS-1 or PYRJN-1 gene; 2) an addition of one or more nucleotides to a NBS-1 or PYRIN-1 gene; 3) a substitution of one or more nucleotides of a NBS-1 or PYRIN- 1 gene; 4) a chromosomal rearrangement of a NBS-1 or PYRJN-1 gene; 5) an alteration in the level ofa messenger RNA transcript of a NBS-1 or PYRIN-1 gene; 6) aberrant modification of a NBS-1 or PYRIN-1 gene, such as ofthe methylation pattern ofthe genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a NBS-1 or PYRIN-1 gene (e.g., caused by a mutation in a splice donor or splice acceptor site);
  • detection ofthe lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241 : 1077-1080; and Nakazawa et al. (1994) Proc. Natl. Acad. Sci.
  • PCR polymerase chain reaction
  • LCR ligation chain reaction
  • This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells ofthe sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a NBS-1 or PYRIN-1 gene under conditions such that hybridization and amplification ofthe NBS-1 or PYRIN-1-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size ofthe amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any ofthe techniques used for detecting mutations described herein.
  • nucleic acid e.g., genomic, mRNA or both
  • Alternative amplification methods include: self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1 177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection ofthe amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
  • mutations in a NBS-1 or PYRIN-1 gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns.
  • sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA.
  • sequence specific ribozymes are used to determine mutations in the sample DNA.
  • genetic mutations in NBS-1 or PYRIN-1 can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al. (1996) Human
  • NBS-1 or PYRIN-1 can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al. supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
  • any of a variety of sequencing reactions known in the art can be used to directly sequence the NBS-1 or PYRIN-1 gene and detect mutations by comparing the sequence ofthe sample NBS-1 or PYRIN-1 with the corresponding wild-type (control) sequence.
  • Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc. Natl. Acad. Sci. USA 74:5463).
  • RNA/RNA or RNA/DNA heteroduplexes Other methods for detecting mutations in the NBS-1 or PYRIN-1 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242).
  • the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NBS-1 or PYRIN-1 sequence with potentially mutant RNA or DNA obtained from a tissue sample.
  • the double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands.
  • RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with SI nuclease to enzymatically digesting the mismatched regions.
  • either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton et al (1988) Proc. Natl Acad Sci USA 85:4397; Saleeba et al (1992) Methods
  • control DNA or RNA can be labeled for detection.
  • the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in
  • NBS-1 or PYRIN-1 cDNAs obtained from samples of cells.
  • the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662).
  • a probe based on a NBS-1 or PYRIN-1 sequence e.g., a wild-type NBS-1 or PYRIN-1 sequence, is hybridized to a cDNA or other DNA product from a test cell(s).
  • the duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.
  • alterations in electrophoretic mobility will be used to identify mutations in NBS-1 or PYRIN-1 genes.
  • SSCP single strand conformation polymorphism
  • Single-stranded DNA fragments of sample and control NBS-1 or PYRIN-1 nucleic acids will be denatured and allowed to renature.
  • the secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change.
  • the DNA fragments may be labeled or detected with labeled probes.
  • the sensitivity ofthe assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence.
  • the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5).
  • the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313 :495).
  • DGGE denaturing gradient gel electrophoresis
  • DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR.
  • a temperature gradient is used in place ofa denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem 265:12753).
  • oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only ifa perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989) Proc. Natl Acad. Sci USA 86:6230).
  • Allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
  • allele specific amplification technology which depends on selective
  • PCR amplification may be used in conjunction with the instant invention.
  • Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner
  • amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end ofthe
  • the methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NBS-1 or PYRIN-1 gene.
  • any cell type or tissue preferably peripheral blood leukocytes, in which NBS-1 or PYRIN-1 is expressed may be utilized in the prognostic assays described herein.
  • Agents, or modulators which have a stimulatory or inhibitory effect on NBS-1 or PYRIN-1 activity can be administered to individuals to treat (prophylactically or therapeutically) disorders (e.g., a neurodegenerative disease such as Alzheimer's disease) associated with aberrant NBS-1 or PYRIN-1 activity.
  • disorders e.g., a neurodegenerative disease such as Alzheimer's disease
  • the pharmacogenomics i.e., the study ofthe relationship between an individual's genotype and that individual's response to a foreign compound or drug
  • the individual may be considered.
  • the pharmacogenomics ofthe individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration ofthe individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NBS-1 or PYRIN-1 protein, expression of NBS-1 or PYRJN-1 nucleic acid, or mutation content of NBS-1 or PYRIN-1 genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment ofthe individual.
  • Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) Clin. Chem. 43(2):254-266.
  • two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms.
  • G6PD glucose-6-phosphate dehydrogenase deficiency
  • oxidant drugs anti-malarials, sulfonamides, analgesics, nitrofurans
  • the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action.
  • drug metabolizing enzymes e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19
  • NAT 2 N-acetyltransferase 2
  • CYP2D6 and CYP2C19 cytochrome P450 enzymes
  • CYP2D6 and CYP2C19 cytochrome P450 enzymes
  • These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations.
  • the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM exhibit no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so-called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
  • NBS-1 or PYRIN-1 protein activity of NBS-1 or PYRIN-1 protein, expression of NBS-1 or PYRIN-1 nucleic acid, or mutation content of NBS-1 or PYRIN-1 genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.
  • pharmacogenetic studies can be used to apply genotyping of polymo ⁇ hic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype.
  • NBS-1 or PYRIN-1 e.g., the ability to modulate aberrant cell proliferation and/or differentiation
  • agents e.g., drugs, compounds
  • PYRIN-1 activity can be monitored in clinical trails of subjects exhibiting decreased NBS-1 or PYRIN-1 gene expression, protein levels, or downregulated NBS-1 or PYRJN-1 activity.
  • the effectiveness of an agent determined by a screening assay to decrease NBS-1 or PYRIN-1 gene expression, protein levels, or downregulated NBS-1 or PYRIN-1 activity can be monitored in clinical trials of subjects exhibiting increased NBS-1 or PYRIN- 1 gene expression, protein levels, or upregulated NBS-1 or PYRIN-1 activity.
  • NBS-1 or PYRIN-1 and, preferably, other genes that have been implicated in, for example, a cellular proliferation disorder can be used as a "read out" or markers ofthe immune responsiveness of a particular cell.
  • genes, including NBS-1 or PYRIN-1, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates NBS-1 or PYRIN-1 activity can be identified.
  • cells can be isolated and RNA prepared and analyzed for the levels of expression of NBS-1 or PYRJN-1 and other genes implicated in the disorder.
  • the levels of gene expression i.e., a gene expression pattern
  • the levels of gene expression can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one ofthe methods as described herein, or by measuring the levels of activity of NBS-1 or PYRIN-1 or other genes.
  • the gene expression pattern can serve as a marker, indicative ofthe physiological response ofthe cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment ofthe individual with the agent.
  • the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration ofthe agent; (ii) detecting the level of expression of a NBS-1 or PYRIN-1 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity ofthe NBS-1 or PYRJN-1 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity ofthe NBS-1 or PYRIN-1 protein, mRNA, or genomic DNA in the pre-administration sample with the NBS-1 or PYRIN-1 protein, mRNA, or genomic DNA in the post administration
  • increased administration ofthe agent may be desirable to increase the expression or activity of NBS-1 or PYRIN-1 to higher levels than detected, i.e., to increase the effectiveness ofthe agent.
  • decreased administration ofthe agent may be desirable to decrease expression or activity of NBS-1 or PYRJN-1 to lower levels than detected, i.e., to decrease the effectiveness ofthe agent. 5. Transcriptional Profiling
  • NBS-1 or PYRIN-1 nucleic acid molecules described herein can be used in transcriptionally profiling.
  • these nucleic acids can be used to examine the expression of NBS-1 or PYRIN-1 in normal tissue or cells and in tissue or cells subject to a disease state, e.g., tissue or cells derived from a patient having a disease of interest or cultured cells which model or reflect a disease state of interest, e.g., cells ofa cultured tumor cell line.
  • a disease state of interest e.g., cells of a cultured tumor cell line.
  • a profile of expression in normal and disease states can be developed. This profile can be used diagnostically and to examine the effectiveness of a therapeutic regime.
  • the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NBS-1 or PYRIN-1 expression or activity, examples of which are provided herein. 1. Prophylactic Methods
  • the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant NBS-1 or PYRIN-1 expression or activity, by administering to the subject an agent which modulates NBS-1 or PYRIN-1 expression or at least one NBS-1 or PYRIN-1 activity.
  • Subjects at risk for a disease which is caused or contributed to by aberrant NBS-1 or PYRIN-1 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
  • Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic ofthe NBS-1 or PYRIN-1 aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
  • NBS-1 or PYRIN-1 agonist or NBS-1 or PYRIN-1 antagonist agent can be used for treating the subject.
  • the appropriate agent can be determined based on screening assays described herein. 2.
  • Another aspect ofthe invention pertains to methods of modulating NBS-1 or PYRIN- 1 expression or activity for therapeutic purposes.
  • the modulatory method ofthe invention involves contacting a cell with an agent that modulates one or more ofthe activities of NBS- 1 or PYRIN-1 protein activity associated with the cell.
  • PYRIN-1 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NBS-1 or PYRIN-1 protein, a peptide, a NBS-1 or PYRJN-1 peptidomimetic, or other small molecule.
  • the agent stimulates one or more of the biological activities of NBS-1 or PYRIN-1 protein. Examples of such stimulatory agents include active NBS-1 or PYRIN-1 protein and a nucleic acid molecule encoding NBS-1 or PYRIN-1 that has been introduced into the cell.
  • the agent inhibits one or more ofthe biological activities of NBS-1 or PYRJN-1 protein.
  • inhibitory agents include antisense NBS-1 or PYRJN-1 nucleic acid molecules and anti-NBS-1 or PYRIN-1 antibodies.
  • modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject).
  • the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NBS-1 or PYRIN-1 protein or nucleic acid molecule or a disorder related to NBS-1 or PYRIN-1 expression or activity.
  • the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) NBS-1 or PYRIN- 1 expression or activity.
  • an agent e.g., an agent identified by a screening assay described herein
  • the method involves administering a NBS- 1 or PYRIN-1 protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NBS-1 or PYRIN-1 expression or activity. Stimulation of NBS-1 or PYRIN-1 activity is desirable in situations in which NBS-1 or PYRIN-1 is abnormally downregulated and/or in which increased NBS-1 or PYRIN-1 activity is likely to have a beneficial effect.
  • NBS-1 or PYRIN-1 activity is desirable in situations in which NBS-1 or PYRIN-1 is abnormally upregulated, e.g., in myocardial infarction, and/or in which decreased NBS-1 or PYRIN-1 activity is likely to have a beneficial effect.
  • This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby inco ⁇ orated by reference.
  • nucleic acid molecules that encode NBS-1 or PYRIN-1 proteins or biologically active portions thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify NBS-1 or PYRIN-1 -encoding nucleic acids (e.g., NBS-1 or PYRJN-1 mRNA) and fragments for use as PCR primers for the amplification or mutation of NBS-1 or PYRIN-1 nucleic acid molecules are useful in the methods ofthe invention.
  • nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
  • the nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
  • An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source ofthe nucleic acid.
  • an "isolated” nucleic acid is free of sequences (preferably protein encoding sequences) that which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends ofthe nucleic acid) in the genomic DNA ofthe organism from which the nucleic acid is derived.
  • the isolated NBS-1 or PYRJN-1 nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA ofthe cell from which the nucleic acid is derived.
  • an "isolated" nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • a nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.
  • NBS-1 or PYRJN-1 nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • Nucleic acid molecules can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.
  • the nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
  • oligonucleotides corresponding to NBS-1 or PYRIN-1 nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
  • the probe/primer typically comprises substantially purified oligonucleotide.
  • the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350 or 400 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID
  • Probe can comprise a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
  • a diagnostic test kit for identifying allelic variants and orthologs ofthe NBS-1 or PYRIN-1 proteins ofthe present invention, identifying cells or tissue which mis-express a NBS-1 or PYRJN-1 protein, such as by measuring a level of a NBS-1 or PYRIN-1 -encoding nucleic acid in a sample of cells from a subject, e.g., detecting NBS-1 or PYRIN-1 mRNA levels or determining whether a genomic NBS-1 or PYRIN-1 gene has been mutated or deleted.
  • a nucleic acid fragment encoding a "biologically active portion" of NBS-1 or PYRIN-1 can be prepared by isolating a portion of SEQ ID NO.T, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the cDNA of ATCC , or the cDNA of ATCC , which encodes a polypeptide having a NBS-1 or PYRIN-1 biological activity, expressing the encoded portion of NBS-1 or PYRIN-1 protein (e.g., by recombinant expression in vitro) and assessing the activity ofthe encoded portion of NBS-1 or PYRIN-1.
  • Nucleic acid molecules that differ from the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the cDNA of ATCC , and the cDNA of
  • PYRIN-1 protein as that encoded by the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:
  • DNA sequence polymo ⁇ hisms that lead to changes in the amino acid sequences of NBS-1 or PYRJN-1 may exist within a population (e.g., the human population).
  • Such genetic polymo ⁇ hism in the NBS-1 or PYRIN-1 gene may exist among individuals within a population due to natural allelic variation, and such variants can be useful in the methods ofthe invention.
  • hybridizes under stringent conditions is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%), 70%, preferably 75% ⁇ ) identical to each other typically remain hybridized to each other.
  • stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
  • An, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C (e.g., 50°C or 60°C or 65°C).
  • the isolated nucleic acid molecule ofthe invention that hybridizes under stringent conditions corresponds to a naturally-occurring nucleic acid molecule.
  • a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in a human cell in nature (e.g., encodes a natural protein).
  • allelic variants of the NBS-1 or PYRIN-1 sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the cDNA of ATCC , or the cDNA of ATCC , thereby leading to changes in the amino acid sequence ofthe encoded protein without altering the functional ability ofthe protein and that such variants are also sueful. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues.
  • non-essential amino acid residue is a residue that can be altered from the wild-type sequence of NBS-1 or PYRIN-1 protein without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity.
  • amino acid residues that are conserved among the NBS-1 or PYRIN-1, proteins of various species are predicted to be particularly unamenable to alteration.
  • conserved domains are less likely to be amenable to mutation.
  • Other amino acid residues e.g., those that are not conserved or only semi-conserved among NBS-1 or PYRIN-1 of various species) may not be essential for activity and thus are likely to be amenable to alteration.
  • NBS-1 or PYRIN-1 proteins that contain changes in amino acid residues that are not essential for activity are useful in the invention.
  • Such NBS-1 or PYRIN-1 proteins differ in amino acid sequence from SEQ ID NO:2 or SEQ ID NO:5 and yet retain biological activity.
  • the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 45% identical, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.
  • the cDNA of ATCC or the cDNA of ATCC can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of NBS- 1 or PYRIN-1 (SEQ ID NO: 1 , SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the cDNA of ATCC , or the cDNA of ATCC ) such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.
  • Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
  • amino acids can be replaced by conservative substitution.
  • conservative amino acid substitution is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • amino acids with basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
  • nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • beta-branched side chains e.g., threonine, valine, isoleucine
  • aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
  • a predicted nonessential amino acid residue in NBS-1 or PYRIN-1 is preferably replaced with another amino acid residue from the same side chain family.
  • mutations can be introduced randomly along all or part of a NBS-1 or PYRIN-1 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NBS-1 or PYRIN-1 biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity ofthe protein can be determined.
  • a mutant NBS-1 or PYRIN-1 protein can be assayed for: (1) the ability to form protein :protein interactions with proteins in the apoptotic signaling pathway; (2) the ability to bind a NBS-1 or PYRJN-1 ligand; or (3) the ability to bind to an intracellular target protein.
  • the present invention encompasses the use of antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
  • the antisense nucleic acid can be complementary to an entire NBS-1 or PYRIN-1 coding strand, or to only a portion thereof, e.g., all or part ofthe protein coding region (or open reading frame).
  • An antisense nucleic acid molecule can be antisense to a noncoding region ofthe coding strand of a nucleotide sequence encoding NBS-1 or PYRIN- 1.
  • the noncoding regions (“5' and 3' untranslated regions") are the 5' and 3' sequences that flank the coding region and are not translated into amino acids.
  • antisense nucleic acids ofthe invention can be designed according to the rules of Watson and Crick base pairing.
  • the antisense nucleic acid molecule can be complementary to the entire coding region of NBS-1 or PYRIN-1 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion ofthe coding or noncoding region of NBS-1 or PYRJN-1 mRNA.
  • the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NBS-1 or PYRIN-1 mRNA.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
  • An antisense nucleic acid ofthe invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid e.g., an antisense oligonucleotide
  • an antisense nucleic acid e.g., an antisense oligonucleotide
  • modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3 -methyl cytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil,
  • 5'-methoxycarboxymethyluracil 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil,
  • the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
  • Antisense nucleic acid molecules are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NBS-1 or PYRIN-1 protein to thereby inhibit expression ofthe protein, e.g., by inhibiting transcription and/or translation.
  • the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove ofthe double helix.
  • An antisense nucleic acid molecule can be administered by direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically.
  • antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens.
  • the antisense nucleic acid molecules can also be delivered to cells using the vectors described herein.
  • vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
  • An antisense nucleic acid molecules can be an ⁇ -anomeric nucleic acid molecule.
  • An ⁇ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids. Res. 15 :6625-6641 ).
  • the antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).
  • Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
  • ribozymes e.g., hammerhead ribozymes (described in Haselhoff and Geriach (1988) Nature 334:585-591)
  • ribozymes can be used to catalytically cleave NBS- 1 or PYRIN-1 mRNA transcripts to thereby inhibit translation of NBS-1 or PYRIN-1 mRNA.
  • a ribozyme having specificity for a NBS-1 or PYRIN-1 -encoding nucleic acid can be designed based upon the nucleotide sequence of a NBS-1 or PYRIN-1 cDNA disclosed herein.
  • a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence ofthe active site is complementary to the nucleotide sequence to be cleaved in a NBS-1 or PYRIN-1 -encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742.
  • NBS-1 or PYRIN-1 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak (1993) Science 261 :1411-1418. Nucleic acid molecules which form triple helical structures are useful in certain aspects ofthe invention.
  • NBS-1 or PYRIN-1 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region ofthe NBS-1 or PYRIN-1 (e.g., the NBS-1 or PYRIN-1 promoter and/or enhancers) to form triple helical structures that prevent transcription ofthe NBS-1 or PYRIN-1 gene in target cells.
  • nucleotide sequences complementary to the regulatory region ofthe NBS-1 or PYRIN-1 e.g., the NBS-1 or PYRIN-1 promoter and/or enhancers
  • NBS-1 and PYRIN-1 nucleic acid molecules can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility ofthe molecule.
  • the deoxyribose phosphate backbone ofthe nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorganic & Medicinal Chemistry 4:5-23).
  • the terms "peptide nucleic acids” or "PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained.
  • PNAs The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.
  • the synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93:14670-675.
  • PNAs of NBS-1 or PYRIN-1 can be used for therapeutic and diagnostic applications.
  • PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication.
  • PNAs of NBS-1 or PYRIN-1 can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., SI nucleases (Hyrup (1996) supra; or as probes or primers for DNA sequence and hybridization (Hyrup (1996) supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93: 14670-675).
  • PNAs of NBS-1 or PYRIN-1 can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of
  • PNA-DNA chimeras or by the use of liposomes or other techniques of drug delivery known in the art.
  • PNA-DNA chimeras of NBS-1 or PYRIN-1 can be generated which may combine the advantageous properties of PNA and DNA.
  • Such chimeras allow DNA recognition enzymes, e.g., RNAse H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity.
  • PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) supra).
  • the synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) supra and Finn et al. (1996) Nucleic Acids Research 24:3357-63.
  • a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g.,
  • 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a between the PNA and the 5' end of DNA (Mag et al. (1989) Nucleic Acid Res. 17:5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) Nucleic Acids Research
  • chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser et al. (1975) Bioorganic Med. Chem. Lett. 5:1119-11124).
  • the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al.
  • oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al. (1988) Bio/Techniques 6:958-976) or intercalating agents (see, e.g., Zon (1988) Pharm. Res. 5:539-549).
  • the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
  • NBS-1 or PYRIN-1 Proteins and Anti-NBS-1 or PYRIN-1 Antibodies are useful in the methods ofthe invention.
  • Native NBS-1 or PYRJN-1 proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques.
  • NBS-1 or PYRIN-1 proteins can also be produced by recombinant DNA techniques. Alternative to recombinant expression, a NBS-1 or
  • PYRIN-1 protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.
  • an “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NBS-1 or PYRJN-1 protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
  • the language “substantially free of cellular material” includes preparations of NBS-1 or PYRJN-1 protein in which the protein is separated from cellular components ofthe cells from which it is isolated or recombinantly produced.
  • NBS-1 or PYRJN-1 protein that is substantially free of cellular material includes preparations of NBS-1 or PYRIN-1 protein having less than about 30%), 20%, 10%), or 5% (by dry weight) of non- NBS-1 or PYRIN-1 protein (also referred to herein as a "contaminating protein").
  • the NBS-1 or PYRIN-1 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%), or 5% ofthe volume ofthe protein preparation.
  • NBS-1 or PYRJN-1 protein When NBS-1 or PYRJN-1 protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis ofthe protein. Accordingly such preparations of NBS-1 or PYRIN- 1 protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or non- NBS-1 or PYRIN-1 chemicals.
  • Biologically active portions of a NBS-1 or PYRJN-1 protein include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence ofthe NBS-1 or PYRIN-1 protein (e.g., the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5), which include less amino acids than the full length NBS-1 or PYRIN-1 protein, and exhibit at least one activity of a NBS-1 or PYRIN-1 protein.
  • biologically active portions comprise a domain or motif with at least one activity ofthe NBS-1 or PYRIN-1 protein.
  • a biologically active portion of a NBS-1 or PYRIN-1 protein can be a polypeptide which is, for example, 10, 25, 50, 72, 100, 125, 150, 175, 200, 225, 250, 272, 300, 325, 350, 375, 400, 425, 450 or more amino acids in length.
  • Preferred biologically active polypeptides include one or more identified NBS-1 or PYRJN-1 structural domains, e.g., the pyrin domain.
  • a useful NBS-1 or PYRIN-1 protein is a protein which includes an amino acid sequence at least about 45%, preferably 55%, 65%, 75%, 85%), 95%, or 99% identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5, and retains the functional activity of the NBS-1 or PYRIN-1 protein of SEQ ID NO:2 or SEQ ID NO:5.
  • the sequences are aligned for optimal comparison pu ⁇ oses (e.g., gaps can be introduced in the sequence ofa first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence).
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the determination of percent homology between two sequences can be accomplished using a mathematical algorithm.
  • a preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Nat'l Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Nat'l Acad. Sci. USA 90:5873-5877.
  • Such an algorithm is inco ⁇ orated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410.
  • Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402.
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is inco ⁇ orated into the ALIGN program (version 2.0) which is part ofthe GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. When utilizing the ALIGN program for comparing nucleic acid sequences, a gap length penalty of 12, and a gap penalty of 4 can be used.
  • Another preferred example of a mathematical algorithm utilized for the comparison of sequences is the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been inco ⁇ orated into the GAP program in the
  • the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com). using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.
  • the percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically exact matches are counted.
  • NBS-1 or PYRIN-1 chimeric or fusion proteins are also useful in the methods ofthe invention.
  • a NBS-1 or PYRIN-1 "chimeric protein” or “fusion protein” comprises a NBS-1 or PYRIN-1 polypeptide operatively linked to a non- NBS-1 or PYRJN-1 polypeptide.
  • a " NBS-1 or PYRIN-1 polypeptide” refers to a polypeptide having an amino acid sequence corresponding to all or a portion (preferably a biologically active portion) of a
  • NBS-1 or PYRIN-1 refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially identical to the NBS-1 or PYRIN-1 protein, e.g., a protein which is different from the NBS-1 or PYRIN-1 proteins and which is derived from the same or a different organism.
  • the term "operatively linked" is intended to indicate that the NBS-1 or PYRIN-1 polypeptide and the non-NBS-1 or PYRIN-1 polypeptide are fused in-frame to each other.
  • the heterologous polypeptide can be fused to the N-terminus or C-terminus of the NBS-1 or PYRIN-1 polypeptide.
  • One useful fusion protein is a GST fusion protein in which the NBS-1 or PYRIN-1 sequences are fused to the C-terminus ofthe GST sequences. Such fusion proteins can facilitate the purification of recombinant NBS-1 or PYRIN-1.
  • the fusion protein contains a signal sequence from another protein.
  • expression and/or secretion of NBS-1 or PYRIN-1 can be increased through use of a heterologous signal sequence.
  • the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Current
  • eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California).
  • useful prokaryotic heterologous signal sequences include the phoA secretory signal (Molecular cloning, Sambrook et al, second edition, Cold spring harbor laboratory press, 1989) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).
  • NBS-1 or PYRIN-1 -immunoglobulin fusion protein in which all or part of NBS-1 or PYRIN-1 is fused to sequences derived from a member ofthe immunoglobulin protein family are also useful.
  • the NBS-1 or PYRIN-1 -immunoglobulin fusion proteins can be inco ⁇ orated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NBS-1 or PYRIN-1 ligand and a NBS-1 or PYRIN-1 protein on the surface ofa cell, to thereby suppress NBS-1 or PYRIN-1 -mediated signal transduction in vivo.
  • the NBS-1 or PYRIN-1 -immunoglobulin fusion proteins can be used to affect the bioavailability of a NBS-1 or PYRIN-1 cognate ligand. Inhibition ofthe NBS-1 or PYRIN-1 ligand/ NBS-1 or PYRIN-1 interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g., promoting or inhibiting) cell survival.
  • the NBS-1 or PYRIN-1 -immunoglobulin fusion proteins can be used as immunogens to produce anti-NBS-1 or PYRIN-1 antibodies in a subject, to purify NBS-1 or PYRIN-1 ligands and in screening assays to identify molecules which inhibit the interaction of NBS-1 or PYRIN-1 with a NBS-1 or PYRIN-1 ligand.
  • a NBS-1 or PYRIN-1 chimeric or fusion proteins can be produced by standard recombinant DNA techniques.
  • DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
  • the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
  • PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons: 1992).
  • anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence
  • expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide).
  • a NBS-1 or PYRJN-1 -encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NBS-1 or PYRIN-1 protein.
  • Variants ofthe NBS-1 or PYRIN-1 proteins which function as either NBS-1 or PYRIN-1 agonists (mimetics) or as NBS-1 or PYRIN-1 antagonists are useful in the invention.
  • Variants ofthe NBS-1 or PYRIN-1 proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation ofthe NBS-1 or PYRIN-1 proteins.
  • An agonist of the NBS-1 or PYRIN-1 protein can retain substantially the same, or a subset, ofthe biological activities ofthe naturally occurring form ofthe NBS-1 or PYRIN-1 protein.
  • An antagonist ofthe NBS-1 or PYRIN-1 protein can inhibit one or more ofthe activities ofthe naturally occurring form ofthe NBS-1 or PYRIN-1 protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NBS-1 or PYRIN-1 protein.
  • specific biological effects can be elicited by treatment with a variant of limited function.
  • Treatment of a subject with a variant having a subset of the biological activities ofthe naturally occurring form ofthe protein can have fewer side effects in a subject relative to treatment with the naturally occurring form ofthe NBS-1 or
  • Variants ofthe NBS-1 or PYRIN-1 protein which function as either NBS-1 or PYRIN-1 agonists (mimetics) or as NBS-1 or PYRIN-1 antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants ofthe NBS-1 or PYRIN-1 protein for NBS-1 or PYRIN-1 protein agonist or antagonist activity.
  • a variegated library of NBS-1 or PYRIN-1 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library.
  • a variegated library of NBS-1 or PYRIN-1 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NBS-1 or PYRIN-1 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NBS-1 or PYRIN-1 sequences therein.
  • NBS-1 or PYRJN-1 Use of a degenerate set of genes allows for the provision, in one mixture, of all ofthe sequences encoding the desired set of potential NBS-1 or PYRJN-1 sequences.
  • Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 1 1 :477).
  • Useful fragments of NBS-1 or PYRIN-1 include fragments comprising or consisting of a domain or subdomain described herein, e.g., LRR or NBS or pyrin domain.
  • libraries of fragments ofthe NBS-1 or PYRIN-1 protein coding sequence can be used to generate a variegated population of NBS-1 or PYRIN-1 fragments for screening and subsequent selection of variants of a NBS-1 or PYRIN-1 protein.
  • a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NBS-1 or PYRIN-1 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/anti sense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with SI nuclease, and ligating the resulting fragment library into an expression vector.
  • an expression library can be derived which encodes N-terminal and internal fragments of various sizes ofthe NBS-1 or PYRIN-1 protein.
  • REM Recursive ensemble mutagenesis
  • NBS-1 or PYRIN-1 protein can be used as an immunogen to generate antibodies that bind NBS-1 or PYRIN-1 using standard techniques for polyclonal and monoclonal antibody preparation.
  • PYRIN-1 protein can be used or, alternatively, the invention provides antigenic peptide fragments of NBS-1 or PYRIN-1 for use as immunogens.
  • the antigenic peptide of NBS-1 or PYRIN-1 comprises at least 8 (preferably 10, 15, 20, or 30) amino acid residues ofthe amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5 and encompasses an epitope of NBS-1 or PYRIN-1 such that an antibody raised against the peptide forms a specific immune complex with NBS-1 or PYRIN-1.
  • Useful antibodies include antibodies which bind to a domain or subdomain of NBS-1 or PYRIN-1 described herein (e.g., a LRR or NBS or pyrin domain).
  • Preferred epitopes encompassed by the antigenic peptide are regions of NBS-1 or PYRJN-1 that are located on the surface ofthe protein, e.g., hydrophilic regions. Other important criteria include a preference for a terminal sequence, high antigenic index (e.g., as predicted by Jameson- Wolf algorithm), ease of peptide synthesis (e.g., avoidance of prolines); and high surface probability (e.g., as predicted by the Emini algorithm; Figures 3 and 6).
  • a NBS-1 or PYRIN-1 immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen.
  • An appropriate immunogenic preparation can contain, for example, recombinantly expressed NBS-1 or PYRJN-1 protein or a chemically synthesized NBS-1 or PYRIN-1 polypeptide.
  • the preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic NBS-1 or PYRIN-1 preparation induces a polyclonal anti-NBS-1 or PYRIN-1 antibody response.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as NBS-1 or PYRJN-1.
  • a molecule which specifically binds to NBS-1 or PYRIN-1 is a molecule which binds NBS-1 or PYRJN-1, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains NBS-1 or PYRIN-1.
  • immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
  • the invention provides polyclonal and monoclonal antibodies that bind NBS-1 or PYRIN-1.
  • a monoclonal antibody composition thus typically displays a single binding affinity for a particular NBS-1 or
  • Polyclonal anti-NBS-1 or PYRIN-1 antibodies can be prepared as described above by immunizing a suitable subject with a NBS-1 or PYRIN-1 immunogen.
  • the anti-NBS-1 or PYRIN-1 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized
  • NBS-1 or PYRIN-1 the antibody molecules directed against NBS-1 or PYRIN-1 can be isolated from the mammal (e.g., from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction.
  • antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (Kozbor et al.
  • an immortal cell line typically a myeloma
  • lymphocytes typically splenocytes
  • lymphocytes typically splenocytes
  • the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes.
  • murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation ofthe present invention with an immortalized mouse cell line, e.g., a myeloma cell line that is sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium").
  • any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NSl/l-Ag4-l, P3-x63-Ag8.653 or Sp2/O-Agl4 myeloma lines. These myeloma lines are available from ATCC.
  • HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG").
  • Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed).
  • Hybridoma cells producing a monoclonal antibody ofthe invention are detected by screening the hybridoma culture supernatants for antibodies that bind NBS-1 or PYRIN-1, e.g., using a standard ELISA assay.
  • a monoclonal anti-NBS-1 or PYRIN-1 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with NBS-1 or PYRIN-1 to thereby isolate immunoglobulin library members that bind NBS-1 or PYRIN- 1.
  • Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP Phage Display Kit, Catalog No. 240612).
  • recombinant anti-NBS-1 or PYRJN-1 antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
  • Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671 ; European Patent Application 184,187; European Patent Application 171 ,496; European Patent Application 173,494; PCT Publication No. WO
  • An anti-NBS-1 or PYRIN-1 antibody (e.g., monoclonal antibody) can be used to isolate NBS-1 or PYRIN-1 by standard techniques, such as affinity chromatography or immunoprecipitation.
  • An anti-NBS-1 or PYRIN-1 antibody can facilitate the purification of natural NBS-1 or PYRIN-1 from cells and of recombinantly produced NBS-1 or PYRIN-1 expressed in host cells.
  • an anti-NBS-1 or PYRIN-1 antibody can be used to detect NBS-1 or PYRIN-1 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the NBS-1 or PYRIN-1 protein.
  • Anti-NBS-1 or PYRIN-1 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example ofa luminescent material includes luminol;
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125 I, ,31 I, 35 S or 3 H
  • an antibody may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion.
  • a cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 -dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.
  • Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6- thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin
  • antimetabolites e.g., methotrexate, 6-mercaptopurine, 6- thioguanine, cytarabine, 5-fluorouracil decarbazine
  • alkylating agents e.g., mechloreth
  • antibiotics e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)
  • anti-mitotic agents e.g., vincristine and vinblastine
  • the conjugates ofthe invention can be used for modifying a given biological response.
  • the drug moiety is not to be construed as limited to classical chemical therapeutic agents.
  • the drug moiety may be a protein or polypeptide possessing a desired biological activity.
  • proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, a- interferon, ⁇ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophase colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or other growth factors.
  • IL-1 interleukin-1
  • IL-2 interleukin-2
  • IL-6
  • an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.
  • antibodies can be administered together or in combination with a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion.
  • a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion.
  • the order of administration ofthe antibody and therapeutic moiety can vary.
  • the antibody is administered concurrently (through the same or different delivery devices, e.g., syringes) with the therapeutic moiety.
  • the antibody can be administered separately and prior to the therapeutic moiety.
  • the therapeutic moiety is administered separately and prior to the antibody. In many embodiments, these administration regimens will be continued for days, months or years.
  • Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a NBS-1 or PYRIN-1 polypeptide, adequate to produce antibody and/or T cell immune response to protect the animal from the diseases hereinbefore mentioned, amongst others.
  • Yet another aspect ofthe invention relates to a method of inducing immunological response in a mammal which comprises, delivering a NBS-1 or PYRIN-1 polypeptide via a vector directing expression of the polynucleotide and coding for the polypeptide in vivo in order to induce such an immunological response to produce antibody to protect the animal from diseases.
  • a further aspect ofthe invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a NBS-1 or PYRIN-1 polypeptide ofthe present invention wherein the composition comprises a polypeptide or polynucleotide of NBS-1 or PYRIN-1.
  • the vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection).
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation instonic with the blood ofthe recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition ofthe sterile liquid carrier immediately prior to use.
  • the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity ofthe formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity ofthe vaccine and can be readily determined by routine experimentation.
  • vectors preferably expression vectors, containing a nucleic acid encoding NBS-1 or PYRJN-1 (or a portion thereof) that are useful in the methods ofthe invention.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • viral vector is another type of vector, wherein additional DNA segments can be ligated into the viral genome.
  • vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operatively linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors).
  • the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
  • Recombinant expression vectors comprise a nucleic acid ofthe invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis ofthe host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed.
  • operably linked is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression ofthe nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
  • regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology
  • Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design ofthe expression vector can depend on such factors as the choice ofthe host cell to be transformed, the level of expression of protein desired, etc.
  • the expression vectors ofthe invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NBS-1 or PYRIN-1 proteins, mutant forms of NBS-1 or PYRJN-1, fusion proteins, etc.).
  • the recombinant expression vectors can be designed for expression of NBS-1 or
  • PYRIN-1 in prokaryotic or eukaryotic cells e.g., bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
  • the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus ofthe recombinant protein.
  • Such fusion vectors typically serve three pu ⁇ oses: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification ofthe recombinant protein by acting as a ligand in affinity purification.
  • a proteolytic cleavage site is introduced at the junction ofthe fusion moiety and the recombinant protein to enable separation ofthe recombinant protein from the fusion moiety subsequent to purification ofthe fusion protein.
  • enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
  • Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
  • GST glutathione S-transferase
  • maltose E binding protein or protein A, respectively, to the target recombinant protein.
  • Suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET l id (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89).
  • Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid t ⁇ -lac fusion promoter.
  • Target gene expression from the pET 1 Id vector relies on transcription from a T7 gnlO-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident e prophage harboring a T7 gnl gene under the transcriptional control ofthe lacUV5 promoter.
  • One strategy to maximize recombinant protein expression in E. coli is to express the protein in a bacterial having an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 1 19-128).
  • Another strategy is to alter the nucleic acid sequence ofthe nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 20:211 1-21 18).
  • Such alteration of nucleic acid sequences ofthe invention can be carried out by standard DNA synthesis techniques.
  • the NBS-1 or PYRIN-1 expression vector is a yeast expression vector.
  • yeast expression vectors for expression in yeast S. cerivisae include pYepSecl (Baldari et al. (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al.
  • ⁇ BS-1 or PYRIN-1 can be expressed in insect cells using baculovirus expression vectors.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al. (1983) Mol Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
  • a nucleic acid ofthe invention is expressed in mammalian cells using a mammalian expression vector.
  • mammalian expression vectors include pCDM8 (Seed (1987) Nature 329:840), pCI (Promega), and pMT2PC (Kaufman et al. (1987) EMBOJ. 6:187-195).
  • the expression vector's control functions are often provided by viral regulatory elements.
  • commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
  • suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al. (supra).
  • the recombinant mammalian expression vector is capable of directing expression ofthe nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
  • tissue-specific regulatory elements are known in the art.
  • suitable tissue-specific promoters include the albumin promoter (liver- specific; Pinkert et al. (1987) Genes Dev. 1 :268-211), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43 :235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989)
  • the invention further provides a recombinant expression vector comprising a DNA molecule ofthe invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription ofthe DNA molecule) of an RNA molecule which is antisense to NBS-1 or PYRIN-1 mRNA.
  • Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression ofthe antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA.
  • the antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
  • host cells into which a recombinant expression vector ofthe invention or isolated nucleic acid molecule ofthe invention has been introduced.
  • the terms "host cell” and “reconf binant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
  • a host cell can be any prokaryotic or eukaryotic cell.
  • NBS-1 or PYRIN-1 protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells).
  • bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells).
  • CHO Chinese hamster ovary cells
  • COS cells Chinese hamster ovary cells
  • Vector DNA or an isolated nucleic acid molecule ofthe invention can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation,
  • a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
  • selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NBS-1 or
  • PYRIN-1 or can be introduced on a separate vector.
  • Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have inco ⁇ orated the selectable marker gene will survive, while the other cells die).
  • a host cell ofthe invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a NBS-1 or PYRIN-1 protein.
  • the invention further provides methods for producing NBS-1 or PYRJN-1 protein using the host cells ofthe invention.
  • the method comprises culturing the host cell of the invention (into which a recombinant expression vector or isolated nucleic acid molecule encoding NBS-1 or PYRJN-1 has been introduced) in a suitable medium such that NBS-1 or PYRIN-1 protein is produced.
  • the method further comprises isolating NBS-1 or PYRIN-1 from the medium or the host cell.
  • NBS-1 and PYRIN-1 nucleic acid molecules can be used in viral gene delivery systems for gene therapy, e.g., adenoviral or retroviral gene delivery systems.
  • NBS-1 and PYRIN-1 nucleic acid molecules can also be used in non-viral gene delivery systems for gene therapy.
  • another aspect ofthe invention pertains to non-viral gene delivery systems, such as plasmid-based gene delivery systems.
  • Non-viral gene delivery systems are described in detail by Huang et al. ((1999) Nonviral Vectors for Gene Therapy, Academic Press, San Diego, CA).
  • Nonviral vectors have several potential advantages over their viral counte ⁇ arts, including: reduced immunogenicity; low acute toxicity; simplicity; and ease of large scale production.
  • Nonviral vectors can be delivered as naked DNA, by bioballistic bombardment, and in various complexes, including liposome/DNA complexes (lipoplexes), polymer/DNA complexes (polyplexes), and liposome/polymer/DNA complexes (lipopolyplexes).
  • Nonviral vectors may be administered by various routes, e.g., intravenous injection, peritoneal injection, intramuscular injection, subcutaneous injection, intratracheal injection, and aerosolization.
  • naked DNA i.e. free from association with, e.g., transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating
  • naked DNA can be expressed at its injection site or at a remote site.
  • naked DNA can be injected directly into skeletal muscle, liver, heart muscle, and tumor tissue.
  • plasmid DNA may need to be protected from degradation by endonucleases during delivery from the site of administration to the site of gene expression.
  • Bioballistic bombardment also known as gene gun, allows for the penetration of target cells in vitro, ex vivo, or in vivo.
  • DNA-coated gold particles are accelerated to a high velocity by an electric arc generated by a high voltage discharge.
  • the method is effective for a variety of organ types, including skin, liver, muscle, spleen, and pancreas.
  • the gene gun transfer method is not dependent upon specific cell surface receptors, cell cycle status, or the size ofthe DNA vector.
  • Useful gene gun devices include the Accell® (PowderJect Vaccines, Inc.) and the HeliosTM (Bio-Rad). These devices create a compressed shock wave of helium gas, accelerating DNA-coated gold (or tungsten) particles to high speed, whereby the particles have sufficient momentum to penetrate a target tissue.
  • Lipoplexes are typically made up of three components: a cationic lipid, a neutral colipid, and plasmid DNA that encodes one or more genes of interest.
  • Commonly used cationic lipids include DOTMA, DMRIE, DC-chol, DOTAP, DMRIE, DDAB, DODAB/C, DOGS, DOSPA, SAINT-n, DOSPER, DPPES, DORIE, GAP-DLRIE. and DOTIM.
  • Dioleoyl (DO) and dimyristoyl (DM) chains are thought to be especially effective for gene delivery.
  • Cationic lipids are typically composed of a positively charged headgroup, a hydrophobic lipid anchor, and a linker that connects the headgroup and anchor.
  • Catioinc lipids used in lipoplexes can be divided into two broad classes: those that use cholesterol as the lipid anchor and those that use diacyl chains of varying lengths and extent of saturation.
  • the number of protonatable amines on the headgroup may affect transfection activity, with multivalent headgroups being generally more active than monovalent headgroups.
  • the linker can be made of a variety of chemical structures, e.g., ether, amide, carbamate, amine, urea, ester, and peptide bonds.
  • Neutral colipids of lipoplexes commonly include DOPE, DOPC, and cholesterol.
  • DOPE is used as the neutral colipid with catioinc lipids that are based on cholesterol (e.g., DC-chol, GL-67) and cholesterol is used as the neutral colipid with cationic lipids that harbor diacyl chains as the hydrophobic anchor (e.g., DOTAP, DOTIM).
  • cholesterol e.g., DC-chol, GL-67
  • cholesterol is used as the neutral colipid with cationic lipids that harbor diacyl chains as the hydrophobic anchor (e.g., DOTAP, DOTIM).
  • Polyplexes are formed when cationic polymers are mixed with DNA.
  • Cationic polymers used to from polyplexes are of two general types: linear polymers such as polylysine and spermine; and the branched chain, spherical, or globular polycations such as polyethyleneimine and dendrimers.
  • Lipopolyplexes are formed by the inco ⁇ oration of polylysine into a lipoplex to form ternary complexes.
  • DNA can be complexed with a natural biopolymer, e.g., gelatin or chitosan, functioning as a gene carrier to form nanospheres.
  • biodegradable nanospheres have several advantages, including the coencapsulation of bioactive agents, e.g. nucleic acids and drugs, and the sustained release ofthe DNA.
  • DNA or chitosan-DNA nanospheres are synthesized by mixing the DNA solution with an aqueous solution of gelatin or chitosan.
  • the effectiveness nonviral vectors may be enhanced by conjugation to ligands that direct the vector either to a particular cell type or to a particular location within a cell.
  • Antibodies and other site-specific proteins can be attached to a vector, e.g., on the surface of the vector or inco ⁇ orated in the membrane. Following injection, these vectors bind efficiently and specifically to a target site.
  • ligands to a cell surface receptor can be inco ⁇ orated into the surface of a liposome by covalently modifying the ligand with a lipid group and adding it during the formation of liposomes.
  • ligands can be incorporated into the nonviral DNA delivery complexes ofthe invention in order to make them more effective for gene delivery: (1) peptides, e.g., peptides having a specific cell surface receptor so that complexes will be targeted to specific cells bearing the receptor; (2) nuclear localization signals, e.g., to promote efficient entry of DNA into the nucleus; (3) pH-sensitive ligands, to encourage endosomal escape; (4) steric stabilizing agents, to prevent destabilization of the complexes after introduction into the biological milieu.
  • Gene chemistry approaches e.g. peptide nucleic acids, can be used to couple ligands to DNA to improve the in vivo bioavailability and expression ofthe DNA.
  • a polypeptide e.g., an antibody
  • nucleic acid molecule or other compound
  • link a polypeptide e.g., an antibody
  • nucleic acid molecule or other compound
  • PNA biotin-conjugated peptide nucleic acid
  • a sequence complementary to the biotin-conjugated PNA clamp is inserted into the gene delivery plasmid.
  • the biotin-conjugated PNA will bind essentially irreversibly to the complementary sequence inserted into the plasmid.
  • a polypeptide, nucleic acid molecule or other compound of interest can be conjugated to streptavidin.
  • the streptavidin conjugate can bind to the biotin-PNA clamp bound to the plasmid.
  • a polypeptide, nucleic acid molecule or other compound can be bound to a gene delivery plasmid such that the polypeptide, nucleic acid molecule or other compound remains bound to the plasmid even within a cell.
  • the PNA clamp-binding site in the plasmid must be chosen so as not to interfere with a needed promoter/enhancer or coding region or otherwise disrupt the expression ofthe gene in the plasmid.
  • An alternative approach employs a maleimide- conjugated PNA clamp.
  • Polypeptides, nucleic acid molecules and other compounds containing a free thiol residue may be conjugated directly to the maleimide-PNA-DNA hybrid. As with the biotin-conjugated method, this conjugation does not disturb the transcriptional activity ofthe plasmid if the PNA-binding site is chosen to be in a region of the plasmid not essential for gene activity. Both of these approaches are described in detail by Zelphati et al. ((2000) BioTechniques 28:304-315). The host cells can also be used to produce. nonhuman transgenic animals.
  • a host cell ofthe invention is a fertilized oocyte or an embryonic stem cell into which NBS-1 or PYRIN- 1 -coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NBS-1 or PYRIN-1 sequences have been introduced into their genome or homologous recombinant animals in which endogenous NBS-1 or PYRJN-1 sequences have been altered.
  • transgenic animal is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells ofthe animal includes a transgene.
  • rodent such as a rat or mouse
  • transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc.
  • a transgene is exogenous DNA which is integrated into the genome ofa cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues ofthe transgenic animal.
  • an "homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NBS-1 or PYRIN-1 gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell ofthe animal, prior to development ofthe animal.
  • a transgenic animal can created by introducing NBS-1 or PYRIN-1 -encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal.
  • Such transgenic animals are useful in screening assays and other methods ofthe invention.
  • the NBS-1 or PYRIN-1 cDNA sequence e.g., that of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the cDNA of ATCC , or the cDNA of ATCC can be introduced as a transgene into the genome of a non-human animal.
  • a nonhuman homolog or ortholog ofthe human NBS-1 or PYRIN-1 gene such as a mouse NBS-1 or PYRIN-1 gene, can be isolated based on hybridization to the human NBS-1 or PYRIN-1 cDNA and used as a transgene.
  • Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression ofthe transgene.
  • a tissue-specific regulatory sequence(s) can be operably linked to the NBS-1 or PYRIN-1 transgene to direct expression of NBS-1 or PYRIN-1 protein to particular cells.
  • Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan,
  • transgenic founder animal can be identified based upon the presence ofthe NBS-1 or PYRIN-1 transgene in its genome and/or expression of NBS-1 or PYRJN-1 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding NBS-1 or PYRIN-1 can further be bred to other transgenic animals carrying other transgenes.
  • a vector is prepared which contains at least a portion of a NBS-1 or PYRIN-1 gene (e.g., a human or a non-human homolog ofthe NBS-1 or PYRIN-1 gene, e.g., a murine NBS-1 or PYRIN-1 gene) into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NBS-1 or PYRIN-1 gene.
  • a NBS-1 or PYRIN-1 gene e.g., a human or a non-human homolog ofthe NBS-1 or PYRIN-1 gene, e.g., a murine NBS-1 or PYRIN-1 gene
  • the vector is designed such that, upon homologous recombination, the endogenous NBS-1 or PYRIN-1 gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector).
  • the vector can be designed such that, upon homologous recombination, the endogenous NBS-1 or PYRIN-1 gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression ofthe endogenous NBS-1 or PYRIN-1 protein).
  • the altered portion ofthe NBS-1 or PYRIN-1 gene is flanked at its 5' and 3' ends by additional nucleic acid ofthe NBS-1 or PYRIN-1 gene to allow for homologous recombination to occur between the exogenous NBS-1 or PYRIN-1 gene carried by the vector and an endogenous NBS-1 or PYRIN-1 gene in an embryonic stem cell.
  • the additional flanking NBS-1 or PYRIN-1 nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene.
  • flanking DNA both at the 5' and 3' ends
  • flanking DNA both at the 5' and 3' ends
  • the vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NBS-1 or PYRIN-1 gene has homologously recombined with the endogenous NBS-1 or PYRIN-1 gene are selected (see, e.g., Li et al. (1992) Cell 69:915).
  • the selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed. (IRL, Oxford, 1987) pp. 1 13-152).
  • a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
  • Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells ofthe animal contain the homologously recombined DNA by germline transmission ofthe transgene.
  • a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251 :1351-1355. If a cre/loxP recombinase system is used to regulate expression ofthe transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required.
  • Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
  • Clones ofthe non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) Nature 385:810-813 and PCT Publication ⁇ os. WO 97/07668 and WO 97/07669.
  • a cell e.g., a somatic cell
  • the quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal ofthe same species from which the quiescent cell is isolated.
  • the reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal.
  • the offspring borne of this female foster animal will be a clone ofthe animal from which the cell, e.g., the somatic cell, is isolated.
  • the expression characteristics of an endogenous ⁇ BS-1 or PYRIN-1 gene within a cell line or microorganism may be modified by inserting a heterologous DNA regulatory element into the genome of a stable cell line or cloned microorganism such that the inserted regulatory element is operatively linked with the endogenous NBS-1 or PYRIN-1 gene.
  • a heterologous DNA regulatory element into the genome of a stable cell line or cloned microorganism such that the inserted regulatory element is operatively linked with the endogenous NBS-1 or PYRIN-1 gene.
  • an endogenous NBS-1 or PYRIN-1 which is normally "transcriptionally silent," i.e.
  • a NBS-1 or PYRJN-1 gene which is normally not expressed, or is expressed only at very low levels in a cell line or microorganism may be activated by inserting a regulatory element which is capable of promoting the expression ofa normally expressed gene product in that cell line or microorganism.
  • a transcriptionally silent, endogenous NBS-1 or PYRJN-1 gene may be activated by insertion of a promiscuous regulatory element that works across cell types.
  • a heterologous regulatory element may be inserted into a stable cell line or cloned microorganism, such that it is operatively linked with an endogenous NBS-1 or PYRIN-1 gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art, and described e.g., in Chappel, U.S. Patent No. 5,272,071 ; PCT publication No. WO 91/06667, published May 16, 1991.
  • compositions suitable for administration can be inco ⁇ orated into pharmaceutical compositions suitable for administration.
  • Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and abso ⁇ tion delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be inco ⁇ orated into the compositions.
  • the invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid ofthe invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid ofthe invention and one or more additional active compounds.
  • the agent which modulates expression or activity may, for example, be a small molecule.
  • such small molecules include peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight les than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1 ,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
  • organic or inorganic compounds i.e., including heteroorganic and organometallic compounds
  • doses of small molecule agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher.
  • the dose(s) ofthe small molecule will vary, for example, depending upon the identity, size, and condition ofthe subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the small molecule to have upon the nucleic acid or polypeptide of the invention.
  • Exemplary doses include milligram or microgram amounts ofthe small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency ofthe small molecule with respect to the expression or activity to be modulated. Such appropriate doses may be determined using the assays described herein.
  • a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained.
  • the specific dose level for any particular subject will depend upon a variety of factors including the activity ofthe specific compound employed, the age, body weight, general health, gender, and diet ofthe subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.
  • a pharmaceutical composition ofthe invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, NJ) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance ofthe required particle size in the case of dispersion and by the use of surfactants.
  • Prevention ofthe action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption ofthe injectable compositions can be brought about by including in the composition an agent which delays abso ⁇ tion, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NBS-1 or PYRIN-1 protein or anti-NBS-1 or PYRIN-1 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • the active compound e.g., a NBS-1 or PYRIN-1 protein or anti-NBS-1 or PYRIN-1 antibody
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder ofthe active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the pu ⁇ ose of oral therapeutic administration, the active compound can be inco ⁇ orated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part ofthe composition.
  • the tablets, pills, capsules, troches and the like can contain any ofthe following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
  • retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Co ⁇ oration and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms ofthe invention are dictated by and directly dependent on the unique characteristics ofthe active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • a therapeutically effective amount of protein or polypeptide ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
  • an effective dosage ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
  • treatment of a subject with a therapeutically effective amount of protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.
  • the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank et al.
  • the nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors.
  • Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470) or by stereotactic injection (see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91 :3054-3057).
  • the pharmaceutical preparation ofthe gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
  • the complete gene delivery vector can be produced intact from recombinant cells, e.g.
  • the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
  • the gene therapy vectors ofthe invention can be either viral or non- viral. Examples of plasmid-based, non-viral vectors are discussed in Huang et al. (1999) Nonviral Vectors for Gene Therapy (supra).
  • a modified plasmid is one example of a non-viral gene delivery system.
  • Peptides, proteins (including antibodies), and oligonucleotides may be stably conjugated to plasmid DNA by methods that do not interfere with the transcriptional activity ofthe plasmid (Zelphati et al. (2000) BioTechniques 28:304-315). The attachment of proteins and/or oligonucleotides may influence the delivery and trafficking ofthe plasmid and thus render it a more effective pharmaceutical composition.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés de thérapie, de criblage et de diagnostic utilisant NBS-1 et PYRINE-1. Les procédés s'appuient sur les interactions entre NBS-1 ou PYRINE-1 et diverses protéines participant aux voies de signalisation apoptotiques et inflammatoires. Elle concerne aussi des procédés pour identifier les modulateurs de ASC et NF-λB.
PCT/US2002/030499 2001-09-26 2002-09-26 Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation WO2003027251A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362604A AU2002362604A1 (en) 2001-09-26 2002-09-26 Novel molecules of the pyrin domain protein family and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US96495501A 2001-09-26 2001-09-26
US09/964,955 2001-09-26
US10/027,629 2001-12-20
US10/027,629 US20020197660A1 (en) 2000-02-17 2001-12-20 Novel molecules of the PYRIN domain protein family and uses thereof
US10/127,516 2002-04-22
US10/127,516 US7300749B2 (en) 2000-02-17 2002-04-22 Molecules of the pyrin domain protein family and uses thereof

Publications (2)

Publication Number Publication Date
WO2003027251A2 true WO2003027251A2 (fr) 2003-04-03
WO2003027251A3 WO2003027251A3 (fr) 2004-01-22

Family

ID=27363065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030499 WO2003027251A2 (fr) 2001-09-26 2002-09-26 Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation

Country Status (3)

Country Link
US (1) US7300749B2 (fr)
AU (1) AU2002362604A1 (fr)
WO (1) WO2003027251A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025591A2 (fr) * 2003-09-17 2005-03-24 Vib Vzw Card derives des caspases
WO2005057218A2 (fr) * 2003-12-02 2005-06-23 Cleveland Clinic Foundation Methodes d'identification de modulateurs de l'apoptose issus de parasites et utilisations correspondantes
US8871215B2 (en) 2004-12-22 2014-10-28 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US9006180B2 (en) 2008-08-01 2015-04-14 Cleveland Biolabs, Inc. Methods for treating tourniquet-induced injuries
US9376473B2 (en) 2011-01-10 2016-06-28 Cleveland Biolabs, Inc. Use of Toll-Like Receptor agonist for treating cancer
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746167A1 (fr) * 2005-07-20 2007-01-24 Apoxis SA Méthode d'identification des components anti-inflammatoires.
WO2007081982A2 (fr) * 2006-01-10 2007-07-19 The Regents Of The University Of Michigan Procédés et compositions pour la médiation de réponses immunitaires et de l'activité adjuvante
WO2015123493A2 (fr) 2014-02-13 2015-08-20 Northwestern University Compositions et méthodes de modulation de réponse immunitaire
KR20220144908A (ko) * 2021-04-20 2022-10-28 아주대학교산학협력단 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286698A (zh) 1998-03-12 2001-03-07 上海第二医科大学 人血管紧张素ⅱ/血管升压素受体样基因
EP1220865A4 (fr) 1999-09-27 2003-04-02 Human Genome Sciences Inc 43 proteines secretees humaines
AU1238201A (en) 1999-10-27 2001-05-08 Millennium Pharmaceuticals, Inc. Novel molecules and the card-related protein family and uses thereof
US20030077699A1 (en) * 2000-09-26 2003-04-24 Reed John C. PAAD domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2003031639A2 (fr) * 2001-10-05 2003-04-17 Ludwig Institute For Cancer Research Cryopyrines isolees, molecules d'acides nucleiques codant ces proteines, et utilisations correspondantes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MANJI ET AL.: 'PYPAFI, a PYRIN-containing Apf1-like protein that assembles with ASC and regulates activation of NF-kB' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 277, no. 13, 29 March 2002, pages 11570 - 11575, XP002967827 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025591A3 (fr) * 2003-09-17 2005-06-30 Vib Vzw Card derives des caspases
WO2005025591A2 (fr) * 2003-09-17 2005-03-24 Vib Vzw Card derives des caspases
WO2005057218A3 (fr) * 2003-12-02 2005-11-17 Cleveland Clinic Foundation Methodes d'identification de modulateurs de l'apoptose issus de parasites et utilisations correspondantes
WO2005057218A2 (fr) * 2003-12-02 2005-06-23 Cleveland Clinic Foundation Methodes d'identification de modulateurs de l'apoptose issus de parasites et utilisations correspondantes
US10086038B2 (en) 2004-12-22 2018-10-02 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US8871215B2 (en) 2004-12-22 2014-10-28 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US8932609B2 (en) 2004-12-22 2015-01-13 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US9139623B2 (en) 2004-12-22 2015-09-22 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US9228000B1 (en) 2004-12-22 2016-01-05 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US10898543B2 (en) 2004-12-22 2021-01-26 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US9457061B2 (en) 2004-12-22 2016-10-04 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US9827289B2 (en) 2004-12-22 2017-11-28 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US10543251B2 (en) 2004-12-22 2020-01-28 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US9006180B2 (en) 2008-08-01 2015-04-14 Cleveland Biolabs, Inc. Methods for treating tourniquet-induced injuries
US10780152B2 (en) 2011-01-10 2020-09-22 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US11628201B2 (en) 2011-01-10 2023-04-18 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US10265390B2 (en) 2011-01-10 2019-04-23 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US9376473B2 (en) 2011-01-10 2016-06-28 Cleveland Biolabs, Inc. Use of Toll-Like Receptor agonist for treating cancer
US10034926B2 (en) 2011-01-10 2018-07-31 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US10730915B2 (en) 2014-07-30 2020-08-04 Genome Protection, Inc. Flagellin-based agents and uses including effective vaccination
US10669316B2 (en) 2014-07-30 2020-06-02 Genome Protection, Inc. Flagellin compositions and uses
US10336793B2 (en) 2014-07-30 2019-07-02 Genome Protection, Inc. Flagellin-based agents and uses including effective vaccination
US10975127B2 (en) 2014-07-30 2021-04-13 Genome Protection, Inc. Flagellin-based agents and uses including effective vaccination
US11034733B2 (en) 2014-07-30 2021-06-15 Genome Protection, Inc. Flagellin compositions and uses
US11542306B2 (en) 2014-07-30 2023-01-03 Genome Protection, Inc. Flagellin-based agents and uses including effective vaccination
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders

Also Published As

Publication number Publication date
WO2003027251A3 (fr) 2004-01-22
AU2002362604A1 (en) 2003-04-07
US20020187922A1 (en) 2002-12-12
US7300749B2 (en) 2007-11-27

Similar Documents

Publication Publication Date Title
EP1196563A2 (fr) Nouvelles molecules de la famille de proteines liee a la card et utilisations de ces dernieres
US7300749B2 (en) Molecules of the pyrin domain protein family and uses thereof
US20060003409A1 (en) Novel molecules of the card-related protein family and uses thereof
US7321028B2 (en) Molecules of the pyrin domain protein family and uses thereof
US7160695B2 (en) Molecules of the PYRIN/NBS/LRR protein family and uses thereof
US7083944B1 (en) Molecules of the card-related protein family and uses thereof
US7648963B2 (en) Molecules of the PYRIN/NBS/LRR protein family and uses thereof
US6936690B2 (en) Molecules of the card-related protein family and uses thereof
US20020028465A1 (en) Novel molecules of the NBS/LRR protein family and uses thereof
US20020197660A1 (en) Novel molecules of the PYRIN domain protein family and uses thereof
US20030224438A1 (en) Novel molecules of the PYRIN/NBS/LRR protein family and uses thereof
US20050287612A1 (en) CARD-4 molecules and uses thereof
US7034135B2 (en) Molecules of the NBS/LRR protein family and uses thereof
WO2001040468A2 (fr) Nouvelles molecules de la famille de proteines de type card et utilisations de ces dernieres
US20020086980A1 (en) Novel molecules of the card-related protein family and uses thereof
US20020150920A1 (en) Novel molecules of the NBS/LRR protein family and uses thereof
WO2002053765A1 (fr) Nouvelles molecules de la famille des proteines liees au card et utilisation de celles-ci
EP1509544A2 (fr) Molecules card-4 et utilisations correspondantes
EP1238074A2 (fr) Molecules de la famille de proteines de type card et utilisations de ces dernieres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP